In response to the COVID-19 pandemic, the DrugBank team has created this information dashboard to provide a comprehensive summary of research in an effort to help interested parties find the information they need quickly and effectively. If you are interested in licensing DrugBank data for commercial use, please contact us.

COVID-19 OUTBREAK SUMMARY: Coronavirus disease 2019 (named COVID-19 on February 11, 2020 by the World Health Organization (WHO) 2,4) was first identified in Wuhan, China near the end of 2019 2. It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV). This name was chosen because the virus is related to the coronavirus that caused the SARS outbreak of 2003. The two viruses are different despite their genetic similarity 1. COVID-19 is believed to be less lethal but much more infectious than SARS-CoV 3. Until the recent outbreak, this virus had not been identified in humans 5.

Disclaimer: This dashboard is intended for research purposes only, and is not to be used for self-diagnosis. If you believe you are experiencing symptoms of COVID-19, please reach out to a medical professional. While we do our best to maintain accuracy and provide up-to-date data and information, we do not guarantee that.
Covid drug dev
COVID-19: Finding the Right Fit

Identifying Potential Treatments Using a Data-Driven Approach

Download the White Paper
COVID-19 Highlights
May 28, 2020

Mounting evidence suggests an involvement of the vascular endothelium in explaining COVID-19 symptomatology. The presence of blood clots combined with symptoms including peripheral hypoxia, heart attacks, and stroke suggest that blood vessel damage may be a hallmark of COVID-19 infection.

May 28, 2020

The LIBERATE clinical trial investigates the efficacy of a unique formulation of ibuprofen in hospitalized UK patients with COVID-19 after animal studies show promising results of ibuprofen ameliorating acute respiratory distress syndrome associated with the infection. Opinions differ over the use of ibuprofen in COVID-19, as there is inconclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients.

May 25, 2020

The World Health Organization has temporarily suspended the hydroxychloroquine arm of the Solidarity Trial for the treatment for COVID-19 due to safety concerns raised in other trials.

May 22, 2020

A multinational registry analysis published in The Lancet involving data for 96 032 patients from 671 hospitals across six continents was unable to confirm a benefit to hydroxychloroquine or chloroquine, either alone or combined with a macrolide antibiotic, for the treatment of Covid-19. Rather, these treatments were associated with decreased survival and increased incidence of ventricular arrhythmias.

May 18, 2020

Moderna reported encouraging results from phase I trials of a novel lipid nanoparticle (NLP)-encapsulated mRNA vaccine (designated mRNA-1273) encoding a stabilized form of the SARS-CoV-2 Spike (S) protein. The phase I results reported that all 45 participants across three dose levels seroconverted within 15 days and, out of eight tested for neutralizing ability, all antibody samples are capable of neutralizing live SARS-Cov-2 in vitro. Moderna has been granted clearance to begin phase II trials as of May 6.

May 16, 2020

Health Canada approves the first Canadian vaccine trials, led by a team of researchers at Dalhousie University in partnership with the Chinese manufacturer, CanSino Biologics. The Canadian Phase I study will build on the Ad5-nCoV vaccine trials that have already begun in China.

May 13, 2020

A possible link is made between COVID-19 and a novel severe Kawasaki-like disease in children, which involves the inflammation in the walls of arteries and other symptoms such as persistent fever, rash, red eyes. Further investigations are ongoing.

May 6, 2020

Laurent Pharmaceuticals, a Montreal-based company, receives Health Canada's approval to initiate its RESOLUTION clinical trial. This Phase II clinical trial investigates the potential therapeutic use of LAU-7b in reducing the severity of COVID-19 and preventing further disease progression into Acute Respiratory Distress Syndrome (ARDS).

May 4, 2020

Researchers in the Netherlands have developed a humanized monoclonal antibody, 47D11, capable of inhibiting both SARS-CoV and SARS-CoV-2 cell infection through binding to the S1B domain of the viral spike protein.

May 1, 2020

FDA grants emergency use authorization for remdesivir

Apr 24, 2020

FDA issues a warning against the use of both hydroxychloroquine and chloroquine outside of medical facilities, due to serious and potentially life-threatening heart rhythm complications associated with both drugs.

Apr 23, 2020

Alongside more than 100 projects for the development of the COVID-19 vaccine around the world, a research team at Oxford University begins the Phase I clinical trial for its ChAdOx1 nCoV-19 vaccine in healthy volunteers.

Mar 28, 2020

FDA grants emergency use authorization for hydroxychloroquine

Mar 18, 2020

The WHO launches the Solidarity clinical trial. The study will compare four treatment options - remdesivir, lopinavir/ritonavir (with and without interferon beta-1a), and hydroxychloroquine or chloroquine - against standard of care to assess their effectiveness against COVID-19.

Mar 16, 2020

Moderna Therapeutics begins Phase I trial for its potential COVID-19 vaccine, mRNA-1273

Experimental Unapproved Treatments for COVID-19
DrugDescription
RemdesivirA nucleoside analog used to treat RNA virus infections including COVID-19.
RitonavirAn HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.
ChloroquineAn antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis.
DarunavirA HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies.
LopinavirAn HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection.
GalidesivirGalidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various...
FavipiravirAn antiviral used to manage influenza, and that has the potential to target other viral infections.
UmifenovirA dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses.
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
TriazavirinAn antiviral used to treat several strains of influenza.
TMC-310911TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections....
mRNA-1273mRNA-1273 is a vaccine developed by Moderna that is currently undergoing investigation for the prophylaxis of SARS-CoV-2 infection. It is a novel mRNA-based vaccine, encapsulated in a lipid nanoparticle, that...
Ad5-nCoVAd5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute...
AZD1222AZD1222 (previously known as ChAdOx1 nCoV-19) is a vaccine currently being investigated for prophylaxis against SARS-CoV-2. The ChAdOx1 viral vector was developed at the University of Oxford and has been...
FingolimodA sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.
MethylprednisoloneA corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
LeronlimabA humanized monoclonal antibody being investigated
AzithromycinA macrolide antibiotic used to treat a variety of bacterial infections.
N4-HydroxycytidineA cytidine analog being investigated to treat COVID-19.
EIDD-2801An orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19.
ElbasvirAn antiviral and NS5A inhibitor used to treat hepatitis C infections.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
GS-441524An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections.
TridecactideAn investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19.
MetenkefalinAn investigational endogenous opioid being studied for the treatment of COVID-19.
VazegepantVazegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will...
IbuprofenAn NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation.
Potential Drug Targets
DrugTarget
RitonavirHuman immunodeficiency virus type 1 protease
DarunavirHuman immunodeficiency virus type 1 protease
LopinavirHuman immunodeficiency virus type 1 protease
MethylprednisoloneGlucocorticoid receptor
LeronlimabC-C chemokine receptor type 5
TocilizumabInterleukin-6 receptor subunit alpha
RemdesivirReplicase polyprotein 1ab
GalidesivirRNA-directed RNA polymerase L
FavipiravirRNA-directed RNA polymerase catalytic subunit
TMC-310911HIV-1 protease
FingolimodSphingosine 1-phosphate receptor 5
BevacizumabVascular endothelial growth factor A
Azithromycin23S ribosomal RNA
ElbasvirNonstructural protein 5A
GS-441524Replicase polyprotein 1ab
VazegepantCalcitonin gene-related peptide type 1 receptor
IbuprofenProstaglandin G/H synthase 2
RemdesivirRNA-directed RNA polymerase L
ChloroquineTumor necrosis factor
ChloroquineGlutathione S-transferase A2
Human interferon betaInterferon alpha/beta receptor 1
BevacizumabComplement C1q subcomponent subunit A
AzithromycinProtein-arginine deiminase type-4
GS-441524RNA-directed RNA polymerase L
MetenkefalinDelta-type opioid receptor
IbuprofenProstaglandin G/H synthase 1
ChloroquineToll-like receptor 9
BevacizumabComplement C1q subcomponent subunit B
MetenkefalinMu-type opioid receptor
BevacizumabComplement C1q subcomponent subunit C
ChloroquineGlutathione S-transferase
FingolimodHistone deacetylase 1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-A
BevacizumabHigh affinity immunoglobulin gamma Fc receptor I
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-a
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-b
IbuprofenApoptosis regulator Bcl-2
ChloroquineHigh mobility group protein B1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-c
IbuprofenThrombomodulin
ChloroquineGlutathione S-transferase Mu 1
FingolimodSphingosine 1-phosphate receptor 1
IbuprofenFatty acid-binding protein, intestinal
ChloroquineAngiotensin-converting enzyme 2
FingolimodSphingosine 1-phosphate receptor 4
MethylprednisoloneAnnexin A1
IbuprofenPeroxisome proliferator-activated receptor gamma
FingolimodSphingosine 1-phosphate receptor 3
IbuprofenCystic fibrosis transmembrane conductance regulator
IbuprofenPeroxisome proliferator-activated receptor alpha
IbuprofenPlatelet glycoprotein Ib alpha chain
IbuprofenProtein S100-A7
RitonavirNuclear receptor subfamily 1 group I member 2
Clinical Trials for COVID-19 and Related Conditions
Start DateDrugIndicationTitlePurposePhaseStatusIdentifier
2020-07-01TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 PatientsTreatment2Not Yet RecruitingNCT04360551
2020-07-01IfenprodilNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized PatientsTreatment2 / 3Not Yet RecruitingNCT04382924
2020-07-01Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)iNOPulse for COVID-19Treatment2Not Yet RecruitingNCT04398290
2020-07-01NitrogenNovel Coronavirus Infectious Disease (COVID-19)iNOPulse for COVID-19Treatment2Not Yet RecruitingNCT04398290
2020-07-01MontelukastNovel Coronavirus Infectious Disease (COVID-19)The COvid-19 Symptom MOntelukast TrialTreatment2 / 3Not Yet RecruitingNCT04389411
2020-07-01AMY-101Novel Coronavirus Infectious Disease (COVID-19)A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)Treatment2Not Yet RecruitingNCT04395456
2020-06-30DuvelisibNovel Coronavirus Infectious Disease (COVID-19)Duvelisib to Combat COVID-19Treatment2Not Yet RecruitingNCT04372602
2020-06-30RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Ruxolitinib to Combat COVID-19Treatment2WithdrawnNCT04354714
2020-06-30LinagliptinNovel Coronavirus Infectious Disease (COVID-19)Effects of DPP4 Inhibition on COVID-19Treatment4Not Yet RecruitingNCT04341935
2020-06-30Tranexamic acidNovel Coronavirus Infectious Disease (COVID-19)Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in InpatientsTreatment2Not Yet RecruitingNCT04338126
2020-06-30Tranexamic acidNovel Coronavirus Infectious Disease (COVID-19)LB1148 for Pulmonary Dysfunction Associated With COVID-19 PneumoniaTreatment2Not Yet RecruitingNCT04390217
2020-06-30Tranexamic acidCOVID-19 PneumoniaLB1148 for Pulmonary Dysfunction Associated With COVID-19 PneumoniaTreatment2Not Yet RecruitingNCT04390217
2020-06-15IxazomibNovel Coronavirus Infectious Disease (COVID-19)Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)Other1Not Yet RecruitingNCT03888534
2020-06-03OxytocinNovel Coronavirus Infectious Disease (COVID-19)Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19Treatment2Not Yet RecruitingNCT04386447
2020-06-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure RiskPreventionNot AvailableNot Yet RecruitingNCT04371926
2020-06-01BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin EnhancementTreatment4Not Yet RecruitingNCT04369794
2020-06-01DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Evaluating AVM0703 for Treatment of COVID-19Treatment1 / 2Not Yet RecruitingNCT04366115
2020-06-01HydrocortisoneNovel Coronavirus Infectious Disease (COVID-19)Evaluating AVM0703 for Treatment of COVID-19Treatment1 / 2Not Yet RecruitingNCT04366115
2020-06-01Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)Treatment2Not Yet RecruitingNCT04344184
2020-06-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19Treatment4Not Yet RecruitingNCT04338906
2020-06-01CamostatNovel Coronavirus Infectious Disease (COVID-19)Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19Treatment4Not Yet RecruitingNCT04338906
2020-06-01AviptadilNovel Coronavirus Infectious Disease (COVID-19)Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19Treatment2 / 3Not Yet RecruitingNCT04360096
2020-06-01BicalutamideNovel Coronavirus Infectious Disease (COVID-19)Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine TherapyTreatment2Not Yet RecruitingNCT04374279
2020-06-01IvermectinNovel Coronavirus Infectious Disease (COVID-19)Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine TherapyTreatment2Not Yet RecruitingNCT04374279
2020-06-01RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Ruxolitinib for COVID-19Treatment2 / 3Not Yet RecruitingNCT04348071
2020-06-01BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Baricitinib for COVID-19Treatment2 / 3Not Yet RecruitingNCT04340232
2020-06-01Human immunoglobulin GNovel Coronavirus Infectious Disease (COVID-19)OCTAGAM 10% THERAPY IN COVID-19 PATIENTS WITH SEVERE DISEASE PROGRESSIONPrevention3Not Yet RecruitingNCT04400058
2020-06-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Nebulized Heparin for the Treatment of COVID-19 Induced Lung InjuryTreatment4Not Yet RecruitingNCT04397510
2020-06-01Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)Nebulized Heparin for the Treatment of COVID-19 Induced Lung InjuryTreatment4Not Yet RecruitingNCT04397510
2020-06-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in VenetoNot AvailableNot Yet RecruitingNCT04393805
2020-06-01UlinastatinNovel Coronavirus Infectious Disease (COVID-19)Ulinastatin for the Treatment of COVID-19 in Hospitalized PatientsTreatment1 / 2Not Yet RecruitingNCT04393311
2020-06-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in SenegalTreatment3Not Yet RecruitingNCT04390594
2020-06-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in SenegalTreatment3Not Yet RecruitingNCT04390594
2020-06-01DipyridamoleNovel Coronavirus Infectious Disease (COVID-19)Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19Treatment2Not Yet RecruitingNCT04391179
2020-06-01LucinactantNovel Coronavirus Infectious Disease (COVID-19)The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19Treatment1 / 2Not Yet RecruitingNCT04389671
2020-06-01TofacitinibNovel Coronavirus Infectious Disease (COVID-19)TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaTreatment2Not Yet RecruitingNCT04390061
2020-06-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaTreatment2Not Yet RecruitingNCT04390061
2020-06-01Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)The Effect of RBT-9 [Stannous Protoporphyrin (SnPP)] on Progression of COVID-19 Infection in High-Risk Individuals (The PREVENT Study)Treatment2Not Yet RecruitingNCT04364763
2020-06-01ProtoporphyrinNovel Coronavirus Infectious Disease (COVID-19)The Effect of RBT-9 [Stannous Protoporphyrin (SnPP)] on Progression of COVID-19 Infection in High-Risk Individuals (The PREVENT Study)Treatment2Not Yet RecruitingNCT04364763
2020-06-01FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19Treatment2Not Yet RecruitingNCT04346628
2020-06-01Povidone-iodineNovel Coronavirus Infectious Disease (COVID-19)PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)Treatment1 / 2Not Yet RecruitingNCT04347954
2020-06-01BudesonideNovel Coronavirus Infectious Disease (COVID-19)Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)Treatment4Not Yet RecruitingNCT04374474
2020-06-01TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab for Patients With Cancer and COVID-19 DiseaseOther2Not Yet RecruitingNCT04370834
2020-06-01ArtesunateNovel Coronavirus Infectious Disease (COVID-19)Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Not Yet RecruitingNCT04387240
2020-06-01ArtemisininNovel Coronavirus Infectious Disease (COVID-19)Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Not Yet RecruitingNCT04387240
2020-06-01TretinoinNovel Coronavirus Infectious Disease (COVID-19)Combination With Alvelestat and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated VaccinesTreatment2Not Yet RecruitingNCT04396067
2020-06-01AlvelestatNovel Coronavirus Infectious Disease (COVID-19)Combination With Alvelestat and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated VaccinesTreatment2Not Yet RecruitingNCT04396067
2020-06-01DeferoxamineNovel Coronavirus Infectious Disease (COVID-19)Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 InfectionTreatment4Not Yet RecruitingNCT04389801
2020-06-01Povidone-iodineNovel Coronavirus Infectious Disease (COVID-19)Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Treatment0RecruitingNCT04385836
2020-06-01RanitidineNovel Coronavirus Infectious Disease (COVID-19)Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine AdministrationBasic Science1Not Yet RecruitingNCT04397445
2020-06-01NiclosamideNovel Coronavirus Infectious Disease (COVID-19)Niclosamide for Mild to Moderate COVID-19Treatment2Not Yet RecruitingNCT04399356
2020-06-01ResiniferatoxinNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is DelayedTreatment3Not Yet RecruitingNCT04386980
2020-06-01DegarelixNovel Coronavirus Infectious Disease (COVID-19)Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring HospitalizationTreatment2Not Yet RecruitingNCT04397718
2020-06-01DoxycyclineNovel Coronavirus Infectious Disease (COVID-19)DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)Treatment3Not Yet RecruitingNCT04371952
2020-05-31RitonavirNovel Coronavirus Infectious Disease (COVID-19)Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19Treatment2Not Yet RecruitingNCT04372628
2020-05-31LopinavirNovel Coronavirus Infectious Disease (COVID-19)Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19Treatment2Not Yet RecruitingNCT04372628
2020-05-31HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19Treatment2Not Yet RecruitingNCT04372628
2020-05-31CamostatNovel Coronavirus Infectious Disease (COVID-19)Camostat Mesylate in COVID-19 OutpatientsTreatment2Not Yet RecruitingNCT04353284
2020-05-30Interferon alfa-2bNovel Coronavirus Infectious Disease (COVID-19)Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer PatientsSupportive Care1 / 2Not Yet RecruitingNCT04379518
2020-05-30Interferon alfaNovel Coronavirus Infectious Disease (COVID-19)Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer PatientsSupportive Care1 / 2Not Yet RecruitingNCT04379518
2020-05-30TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)Treatment3RecruitingNCT04361552
2020-05-29PembrolizumabNovel Coronavirus Infectious Disease (COVID-19)Checkpoint Blockade in COVID-19 PandemicTreatment2RecruitingNCT04335305
2020-05-29TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Checkpoint Blockade in COVID-19 PandemicTreatment2RecruitingNCT04335305
2020-05-29SitagliptinNovel Coronavirus Infectious Disease (COVID-19)The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic PatientsTreatment3Not Yet RecruitingNCT04365517
2020-05-28OtilimabNovel Coronavirus Infectious Disease (COVID-19)Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related DiseaseTreatment2Not Yet RecruitingNCT04376684
2020-05-27Poractant alfaNovel Coronavirus Infectious Disease (COVID-19)Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19Treatment2Not Yet RecruitingNCT04384731
2020-05-26CiclesonideNovel Coronavirus Infectious Disease (COVID-19)A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 PatientsTreatment3Not Yet RecruitingNCT04377711
2020-05-25DAS-181Novel Coronavirus Infectious Disease (COVID-19)DAS181 for STOP COVID-19Treatment2 / 3Not Yet RecruitingNCT04354389
2020-05-25Tranexamic acidNovel Coronavirus Infectious Disease (COVID-19)TXA and Corona Virus 2019 (COVID19) in OutpatientsTreatment2Not Yet RecruitingNCT04338074
2020-05-25AzithromycinNovel Coronavirus Infectious Disease (COVID-19)International ALLIANCE Study of Therapies to Prevent Progression of COVID-19Treatment2Not Yet RecruitingNCT04395768
2020-05-25HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)International ALLIANCE Study of Therapies to Prevent Progression of COVID-19Treatment2Not Yet RecruitingNCT04395768
2020-05-22MavrilimumabNovel Coronavirus Infectious Disease (COVID-19)Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)Treatment2Not Yet RecruitingNCT04397497
2020-05-22AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Azithromycin for COVID-19 Treatment in Outpatients NationwideTreatment3RecruitingNCT04332107
2020-05-21DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical TrialTreatment3RecruitingNCT04395105
2020-05-20LevamisoleNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Not Yet RecruitingNCT04360122
2020-05-20Inosine pranobexNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Not Yet RecruitingNCT04360122
2020-05-20MavrilimumabNovel Coronavirus Infectious Disease (COVID-19)Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2RecruitingNCT04399980
2020-05-20ImatinibNovel Coronavirus Infectious Disease (COVID-19)Trial of Imatinib for Hospitalized Adults With COVID-19Treatment3Not Yet RecruitingNCT04394416
2020-05-20BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Baricitinib Compared to Standard Therapy in Patients With COVID-19Treatment2Not Yet RecruitingNCT04393051
2020-05-20DapagliflozinNovel Coronavirus Infectious Disease (COVID-19)mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2 / 3Not Yet RecruitingNCT04393246
2020-05-20AmbrisentanNovel Coronavirus Infectious Disease (COVID-19)mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2 / 3Not Yet RecruitingNCT04393246
2020-05-20AtorvastatinNovel Coronavirus Infectious Disease (COVID-19)Atorvastatin as Adjunctive Therapy in COVID-19Treatment2Not Yet RecruitingNCT04380402
2020-05-20HoneyNovel Coronavirus Infectious Disease (COVID-19)Honey & Nigella Sativa-COVID-Pakistan Trial Against COVID-19Treatment3RecruitingNCT04347382
2020-05-20TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20EprosartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20IrbesartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20CandesartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20LosartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20OlmesartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-20ValsartanNovel Coronavirus Infectious Disease (COVID-19)Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Not Yet RecruitingNCT04394117
2020-05-19HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - CanadaPrevention3Not Yet RecruitingNCT04397328
2020-05-18BudesonideNovel Coronavirus Infectious Disease (COVID-19)Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of SeverityTreatment3RecruitingNCT04361474
2020-05-16BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Treatment2 / 3Not Yet RecruitingNCT04320277
2020-05-16RitonavirNovel Coronavirus Infectious Disease (COVID-19)Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Treatment2 / 3Not Yet RecruitingNCT04320277
2020-05-16LopinavirNovel Coronavirus Infectious Disease (COVID-19)Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Treatment2 / 3Not Yet RecruitingNCT04320277
2020-05-15RitonavirNovel Coronavirus Infectious Disease (COVID-19)Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Not Yet RecruitingNCT04386070
2020-05-15LopinavirNovel Coronavirus Infectious Disease (COVID-19)Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Not Yet RecruitingNCT04386070
2020-05-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Not Yet RecruitingNCT04386070
2020-05-15HeparinNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19Treatment2Not Yet RecruitingNCT04377997
2020-05-15EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19Treatment2Not Yet RecruitingNCT04377997
2020-05-15RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)Treatment2Not Yet RecruitingNCT04366232
2020-05-15AnakinraNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)Treatment2Not Yet RecruitingNCT04366232
2020-05-15LopinavirNovel Coronavirus Infectious Disease (COVID-19)Xiyanping Injection for the Treatment of New Coronavirus Infected PneumoniaNot AvailableNot Yet RecruitingNCT04275388
2020-05-15RitonavirNovel Coronavirus Infectious Disease (COVID-19)Xiyanping Injection for the Treatment of New Coronavirus Infected PneumoniaNot AvailableNot Yet RecruitingNCT04275388
2020-05-15AviptadilNovel Coronavirus Infectious Disease (COVID-19)Intravenous Aviptadil for COVID-19 Associated Acute Respiratory DistressTreatment2Enrolling by InvitationNCT04311697
2020-05-15EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) TrialPrevention2Not Yet RecruitingNCT04354155
2020-05-15BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic TrialTreatment2Not Yet RecruitingNCT04399798
2020-05-15TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Telmisartan for Treatment of COVID-19 PatientsTreatment2Not Yet RecruitingNCT04355936
2020-05-15LinagliptinNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19Treatment3Not Yet RecruitingNCT04371978
2020-05-15CiclesonideNovel Coronavirus Infectious Disease (COVID-19)Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)Treatment2Not Yet RecruitingNCT04381364
2020-05-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)Prevention2 / 3Not Yet RecruitingNCT04400019
2020-05-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.PreventionNot AvailableNot Yet RecruitingNCT04370015
2020-05-15LopinavirCOVID-19 PneumoniaXiyanping Injection for the Treatment of New Coronavirus Infected PneumoniaNot AvailableNot Yet RecruitingNCT04275388
2020-05-15RitonavirCOVID-19 PneumoniaXiyanping Injection for the Treatment of New Coronavirus Infected PneumoniaNot AvailableNot Yet RecruitingNCT04275388
2020-05-14IvermectinNovel Coronavirus Infectious Disease (COVID-19)Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal TrialTreatment2RecruitingNCT04390022
2020-05-14FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Favipiravir vs Hydroxychloroquine in COVID -19Treatment2 / 3Not Yet RecruitingNCT04387760
2020-05-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Favipiravir vs Hydroxychloroquine in COVID -19Treatment2 / 3Not Yet RecruitingNCT04387760
2020-05-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 InfectionPrevention3RecruitingNCT04372017
2020-05-14Interleukin-7Novel Coronavirus Infectious Disease (COVID-19)InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK CohortTreatment2RecruitingNCT04379076
2020-05-14AlteplaseNovel Coronavirus Infectious Disease (COVID-19)Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 InfectionTreatment2RecruitingNCT04357730
2020-05-14EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 PatientsTreatment3RecruitingNCT04366960
2020-05-13AzithromycinNovel Coronavirus Infectious Disease (COVID-19)A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)Treatment3Not Yet RecruitingNCT04381962
2020-05-13NadroparinNovel Coronavirus Infectious Disease (COVID-19)Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19Prevention4RecruitingNCT04373707
2020-05-13DalteparinNovel Coronavirus Infectious Disease (COVID-19)Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19Prevention4RecruitingNCT04373707
2020-05-13EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19Prevention4RecruitingNCT04373707
2020-05-13HeparinNovel Coronavirus Infectious Disease (COVID-19)Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19Prevention4RecruitingNCT04373707
2020-05-13TinzaparinNovel Coronavirus Infectious Disease (COVID-19)Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19Prevention4RecruitingNCT04373707
2020-05-13PrazosinNovel Coronavirus Infectious Disease (COVID-19)Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)Treatment2RecruitingNCT04365257
2020-05-13Peginterferon lambda-1aNovel Coronavirus Infectious Disease (COVID-19)Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19Treatment2RecruitingNCT04354259
2020-05-12MannitolNovel Coronavirus Infectious Disease (COVID-19)#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19Treatment2 / 3Not Yet RecruitingNCT04385264
2020-05-12HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19Treatment2 / 3Not Yet RecruitingNCT04385264
2020-05-12AcalabrutinibNovel Coronavirus Infectious Disease (COVID-19)Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.Treatment2Not Yet RecruitingNCT04380688
2020-05-12FamotidineNovel Coronavirus Infectious Disease (COVID-19)Famotidine Outpatient COVID-19 Treatment StudyNot AvailableActive Not RecruitingNCT04389567
2020-05-12Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Inhaled Nitric Oxide for Preventing Progression in COVID-19Treatment2RecruitingNCT04388683
2020-05-12PlitidepsinNovel Coronavirus Infectious Disease (COVID-19)Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19Treatment1RecruitingNCT04382066
2020-05-12AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)Treatment2Not Yet RecruitingNCT04392128
2020-05-12HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)Treatment2Not Yet RecruitingNCT04392128
2020-05-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaTreatment2 / 3Not Yet RecruitingNCT04359095
2020-05-11RitonavirNovel Coronavirus Infectious Disease (COVID-19)Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaTreatment2 / 3Not Yet RecruitingNCT04359095
2020-05-11LopinavirNovel Coronavirus Infectious Disease (COVID-19)Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaTreatment2 / 3Not Yet RecruitingNCT04359095
2020-05-11AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaTreatment2 / 3Not Yet RecruitingNCT04359095
2020-05-11AcalabrutinibNovel Coronavirus Infectious Disease (COVID-19)Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.Treatment2Not Yet RecruitingNCT04346199
2020-05-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)PROLIFIC ChemoprophylaxisTrial (COVID-19)Prevention3RecruitingNCT04352933
2020-05-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare ProfessionalsPrevention0Enrolling by InvitationNCT04340349
2020-05-11BromhexineNovel Coronavirus Infectious Disease (COVID-19)Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare ProfessionalsPrevention0Enrolling by InvitationNCT04340349
2020-05-11IvermectinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19Treatment2RecruitingNCT04381884
2020-05-08AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Novel Regimens in COVID-19 TreatmentTreatment3Not Yet RecruitingNCT04382846
2020-05-08IvermectinNovel Coronavirus Infectious Disease (COVID-19)Novel Regimens in COVID-19 TreatmentTreatment3Not Yet RecruitingNCT04382846
2020-05-08ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Novel Regimens in COVID-19 TreatmentTreatment3Not Yet RecruitingNCT04382846
2020-05-08NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Novel Regimens in COVID-19 TreatmentTreatment3Not Yet RecruitingNCT04382846
2020-05-08RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)Treatment3RecruitingNCT04377620
2020-05-08EtoposideNovel Coronavirus Infectious Disease (COVID-19)Etoposide in Patients With COVID-19 InfectionSupportive Care2RecruitingNCT04356690
2020-05-08Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 InfectionPrevention2RecruitingNCT04337918
2020-05-08HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08RitonavirNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08LopinavirNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08HeparinNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Supportive CareNot AvailableRecruitingNCT04380818
2020-05-08TocilizumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04372186
2020-05-08RavulizumabNovel Coronavirus Infectious Disease (COVID-19)mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4RecruitingNCT04390464
2020-05-08BaricitinibNovel Coronavirus Infectious Disease (COVID-19)mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4RecruitingNCT04390464
2020-05-08TocilizumabCOVID-19 PneumoniaA Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04372186
2020-05-07HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving RadiotherapyPrevention2RecruitingNCT04381988
2020-05-07ClazakizumabNovel Coronavirus Infectious Disease (COVID-19)Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2RecruitingNCT04363502
2020-05-06ClevudineNovel Coronavirus Infectious Disease (COVID-19)The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19Treatment2RecruitingNCT04347915
2020-05-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19Treatment2RecruitingNCT04347915
2020-05-06ClarithromycinNovel Coronavirus Infectious Disease (COVID-19)Anti-inflammatory Clarithromycin for Improving COVID-19 Infection EarlyPrevention2RecruitingNCT04398004
2020-05-06EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Covid-19 Associated CoagulopathyTreatment4Not Yet RecruitingNCT04360824
2020-05-06IbrutinibNovel Coronavirus Infectious Disease (COVID-19)Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With CoronaVirus Induced Disease 2019 (COVID-19) and Pulmonary DistressTreatment2Not Yet RecruitingNCT04375397
2020-05-05CaptoprilNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)Treatment2Not Yet RecruitingNCT04355429
2020-05-05Methylene blueNovel Coronavirus Infectious Disease (COVID-19)Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19Treatment2Not Yet RecruitingNCT04376788
2020-05-05RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 InfectionsNot AvailableRecruitingNCT04365725
2020-05-05LeflunomideNovel Coronavirus Infectious Disease (COVID-19)Leflunomide in Mild COVID-19 PatientsTreatment1RecruitingNCT04361214
2020-05-05HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)Treatment4Not Yet RecruitingNCT04351919
2020-05-05AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)Treatment4Not Yet RecruitingNCT04351919
2020-05-05HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Asymptomatic COVID-19 TrialTreatment2Not Yet RecruitingNCT04374552
2020-05-05AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Asymptomatic COVID-19 TrialTreatment2Not Yet RecruitingNCT04374552
2020-05-05AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic TrialTreatment3Not Yet RecruitingNCT04383717
2020-05-05HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic TrialTreatment3Not Yet RecruitingNCT04383717
2020-05-05LevamisoleNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic TrialTreatment3Not Yet RecruitingNCT04383717
2020-05-05Inosine pranobexNovel Coronavirus Infectious Disease (COVID-19)Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic TrialTreatment3Not Yet RecruitingNCT04383717
2020-05-05HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19Treatment2RecruitingNCT04379492
2020-05-04HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)Treatment3Not Yet RecruitingNCT04361461
2020-05-04IvermectinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 InfectionTreatment3RecruitingNCT04391127
2020-05-04HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 InfectionTreatment3RecruitingNCT04391127
2020-05-04LanadelumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH DeficiencyTreatment3Active Not RecruitingNCT04206605
2020-05-04OzoneNovel Coronavirus Infectious Disease (COVID-19)Ozone Auto-hemotherapy for COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04370223
2020-05-04DeferoxamineNovel Coronavirus Infectious Disease (COVID-19)Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in TunisiaTreatment3Not Yet RecruitingNCT04361032
2020-05-04TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in TunisiaTreatment3Not Yet RecruitingNCT04361032
2020-05-04ZincNovel Coronavirus Infectious Disease (COVID-19)A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare WorkersPrevention3Not Yet RecruitingNCT04377646
2020-05-04HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare WorkersPrevention3Not Yet RecruitingNCT04377646
2020-05-04OzoneCOVID-19 PneumoniaOzone Auto-hemotherapy for COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04370223
2020-05-02LiothyronineNovel Coronavirus Infectious Disease (COVID-19)Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 InfectionTreatment2Not Yet RecruitingNCT04348513
2020-05-02AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 PatientsTreatment3Not Yet RecruitingNCT04371406
2020-05-02HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 PatientsTreatment3Not Yet RecruitingNCT04371406
2020-05-02HeparinNovel Coronavirus Infectious Disease (COVID-19)Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19Treatment4RecruitingNCT04367831
2020-05-02EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19Treatment4RecruitingNCT04367831
2020-05-01ChlorpromazineNovel Coronavirus Infectious Disease (COVID-19)Administration of Chloropromazine as a Treatment for COVID-19Treatment1 / 2Not Yet RecruitingNCT04354805
2020-05-01Povidone-iodineNovel Coronavirus Infectious Disease (COVID-19)Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19Treatment2Not Yet RecruitingNCT04371965
2020-05-01AnakinraNovel Coronavirus Infectious Disease (COVID-19)Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19Treatment3Not Yet RecruitingNCT04362111
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19Treatment3Not Yet RecruitingNCT04360759
2020-05-01ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19Treatment3Not Yet RecruitingNCT04360759
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19Treatment2 / 3Not Yet RecruitingNCT04361318
2020-05-01NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19Treatment2 / 3Not Yet RecruitingNCT04361318
2020-05-01DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical TrialTreatment2Not Yet RecruitingNCT04360876
2020-05-01IvermectinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin and Nitazoxanide Combination Therapy for COVID-19Treatment2 / 3Not Yet RecruitingNCT04360356
2020-05-01NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Ivermectin and Nitazoxanide Combination Therapy for COVID-19Treatment2 / 3Not Yet RecruitingNCT04360356
2020-05-01MethotrexateNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 PatientsTreatment1 / 2Not Yet RecruitingNCT04352465
2020-05-01RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDSTreatment2Not Yet RecruitingNCT04359290
2020-05-01Acetylsalicylic acidNovel Coronavirus Infectious Disease (COVID-19)The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 HospitalizationsTreatment2Not Yet RecruitingNCT04363840
2020-05-01TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 InfectionTreatment2RecruitingNCT04377659
2020-05-01TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19Treatment2Not Yet RecruitingNCT04377503
2020-05-01Methylprednisolone hemisuccinateNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19Treatment2Not Yet RecruitingNCT04377503
2020-05-01FluoxetineNovel Coronavirus Infectious Disease (COVID-19)Fluoxetine to Reduce Intubation and Death After COVID19 InfectionTreatment4RecruitingNCT04377308
2020-05-01BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)Using BCG Vaccine to Protect Health Care Workers in the COVID-19 PandemicPrevention3Not Yet RecruitingNCT04373291
2020-05-01Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 TreatmentTreatment2Not Yet RecruitingNCT04363216
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)The University of the Philippines Hydroxychloroquine PEP Against COVID-19 TrialPrevention3Not Yet RecruitingNCT04364815
2020-05-01IsotretinoinNovel Coronavirus Infectious Disease (COVID-19)Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Not Yet RecruitingNCT04382950
2020-05-01Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)Treatment1Not Yet RecruitingNCT04383002
2020-05-01ZilucoplanNovel Coronavirus Infectious Disease (COVID-19)Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory FailureTreatment2Not Yet RecruitingNCT04382755
2020-05-01ZanubrutinibNovel Coronavirus Infectious Disease (COVID-19)Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsTreatment2Not Yet RecruitingNCT04382586
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia TrialTreatment4Not Yet RecruitingNCT04382625
2020-05-01ClazakizumabNovel Coronavirus Infectious Disease (COVID-19)Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Not Yet RecruitingNCT04381052
2020-05-01VidofludimusNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)Treatment2 / 3Not Yet RecruitingNCT04379271
2020-05-01CalciumNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)Treatment2 / 3Not Yet RecruitingNCT04379271
2020-05-01CalciumNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)Not AvailableRecruitingNCT04379310
2020-05-01ProtoporphyrinNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Sn-protoporphyrin IX (SnPPIX) and Sulfonatoporphyrin(TPPS)Against Covid-19Treatment1Not Yet RecruitingNCT04371822
2020-05-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )TreatmentNot AvailableNot Yet RecruitingNCT04372589
2020-05-01Ad5-nCoVNovel Coronavirus Infectious Disease (COVID-19)Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in CanadaPrevention1 / 2Not Yet RecruitingNCT04398147
2020-05-01ABX-464Novel Coronavirus Infectious Disease (COVID-19)ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19Treatment2 / 3RecruitingNCT04393038
2020-05-01IvermectinNovel Coronavirus Infectious Disease (COVID-19)New Antiviral Drugs for Treatment of COVID-19Treatment3Not Yet RecruitingNCT04392427
2020-05-01NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)New Antiviral Drugs for Treatment of COVID-19Treatment3Not Yet RecruitingNCT04392427
2020-05-01RibavirinNovel Coronavirus Infectious Disease (COVID-19)New Antiviral Drugs for Treatment of COVID-19Treatment3Not Yet RecruitingNCT04392427
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)PROphylaxis for paTiEnts at Risk of COVID-19 infecTionPrevention2 / 3Not Yet RecruitingNCT04389359
2020-05-01TamoxifenNovel Coronavirus Infectious Disease (COVID-19)Combination Therapy With Isotretinoin and Tamoxifen May Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Not Yet RecruitingNCT04389580
2020-05-01IsotretinoinNovel Coronavirus Infectious Disease (COVID-19)Combination Therapy With Isotretinoin and Tamoxifen May Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Not Yet RecruitingNCT04389580
2020-05-01AcetylcysteineNovel Coronavirus Infectious Disease (COVID-19)A Study of N-acetylcysteine in Patients With COVID-19 InfectionTreatment2RecruitingNCT04374461
2020-05-01HydrocortisoneNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04359511
2020-05-01PrednisoneNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04359511
2020-05-01RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)Treatment3RecruitingNCT04362137
2020-05-01ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)Treatment2RecruitingNCT04355143
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2RecruitingNCT04358068
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2RecruitingNCT04358068
2020-05-01AlmitrineNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related PneumoniaTreatment3Not Yet RecruitingNCT04357457
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Not Yet RecruitingNCT04347512
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Not Yet RecruitingNCT04347512
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical StudyTreatment2 / 3Not Yet RecruitingNCT04332835
2020-05-01ChloroquineNovel Coronavirus Infectious Disease (COVID-19)CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTIONPrevention3Not Yet RecruitingNCT04333732
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare WorkersPrevention3Not Yet RecruitingNCT04371523
2020-05-01RavulizumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe PneumoniaTreatment3Not Yet RecruitingNCT04369469
2020-05-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19Not AvailableNot Yet RecruitingNCT04359212
2020-05-01FondaparinuxNovel Coronavirus Infectious Disease (COVID-19)Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19Not AvailableNot Yet RecruitingNCT04359212
2020-05-01RivaroxabanNovel Coronavirus Infectious Disease (COVID-19)Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION TrialTreatment4Not Yet RecruitingNCT04394377
2020-05-01EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION TrialTreatment4Not Yet RecruitingNCT04394377
2020-05-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION TrialTreatment4Not Yet RecruitingNCT04394377
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19Prevention2RecruitingNCT04359537
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaReTreatment3Not Yet RecruitingNCT04373733
2020-05-01Zinc sulfateNovel Coronavirus Infectious Disease (COVID-19)A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaReTreatment3Not Yet RecruitingNCT04373733
2020-05-01FavipiravirNovel Coronavirus Infectious Disease (COVID-19)A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaReTreatment3Not Yet RecruitingNCT04373733
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaReTreatment3Not Yet RecruitingNCT04373733
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare WorkersPreventionNot AvailableNot Yet RecruitingNCT04384458
2020-05-01IbuprofenNovel Coronavirus Infectious Disease (COVID-19)Inhaled Ibuprofen to Treat COVID-19TreatmentNot AvailableActive Not RecruitingNCT04382768
2020-05-01Povidone-iodineNovel Coronavirus Infectious Disease (COVID-19)SINUS WASH Pilot Study in Adults Testing Positive for COVID-19Treatment1RecruitingNCT04393792
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 PatientsTreatmentNot AvailableNot Yet RecruitingNCT04374903
2020-05-01SirolimusNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 PatientsTreatmentNot AvailableNot Yet RecruitingNCT04374903
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 PatientsTreatmentNot AvailableNot Yet RecruitingNCT04374903
2020-05-01MetenkefalinNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2 / 3RecruitingNCT04374032
2020-05-01TridecactideNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2 / 3RecruitingNCT04374032
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3RecruitingNCT04358081
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3RecruitingNCT04358081
2020-05-01Dornase alfaNovel Coronavirus Infectious Disease (COVID-19)Nebulised Dornase Alfa for Treatment of COVID-19Treatment2Not Yet RecruitingNCT04359654
2020-05-01SarilumabNovel Coronavirus Infectious Disease (COVID-19)Study on the Use of Sarilumab in Patients With COVID-19 InfectionTreatment0Not Yet RecruitingNCT04386239
2020-05-01FavipiravirNovel Coronavirus Infectious Disease (COVID-19)FAvipiravir and HydroxyChloroquine Combination TherapyTreatmentNot AvailableNot Yet RecruitingNCT04392973
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)FAvipiravir and HydroxyChloroquine Combination TherapyTreatmentNot AvailableNot Yet RecruitingNCT04392973
2020-05-01IsotretinoinNovel Coronavirus Infectious Disease (COVID-19)Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19 (Randomized)Treatment2 / 3Not Yet RecruitingNCT04353180
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19Treatment3Not Yet RecruitingNCT04372082
2020-05-01NiclosamideNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19Treatment3Not Yet RecruitingNCT04372082
2020-05-01DiltiazemNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19Treatment3Not Yet RecruitingNCT04372082
2020-05-01CamostatNovel Coronavirus Infectious Disease (COVID-19)Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2RecruitingNCT04374019
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2RecruitingNCT04374019
2020-05-01IvermectinNovel Coronavirus Infectious Disease (COVID-19)Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2RecruitingNCT04374019
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2RecruitingNCT04374019
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Not Yet RecruitingNCT04335084
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Not Yet RecruitingNCT04334512
2020-05-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)A Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Not Yet RecruitingNCT04334512
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Effect of Hydroxychloroquine in COVID-19 Positive Pregnant WomenTreatment2Not Yet RecruitingNCT04354441
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)Treatment2Not Yet RecruitingNCT04363827
2020-05-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)Treatment4Not Yet RecruitingNCT04363866
2020-05-01SirolimusNovel Coronavirus Infectious Disease (COVID-19)Sirolimus in COVID-19 Phase 1Treatment1RecruitingNCT04371640
2020-05-01HeparinNovel Coronavirus Infectious Disease (COVID-19)Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory FailureTreatment2 / 3Not Yet RecruitingNCT04389840
2020-05-01Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory FailureTreatment2 / 3Not Yet RecruitingNCT04389840
2020-05-01Peginterferon lambda-1aNovel Coronavirus Infectious Disease (COVID-19)Interferon Lambda Therapy for COVID-19Treatment2Not Yet RecruitingNCT04388709
2020-05-01HydroxychloroquineCOVID-19 PneumoniaHydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia TrialTreatment4Not Yet RecruitingNCT04382625
2020-04-30NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)Prevention3Not Yet RecruitingNCT04343248
2020-04-30NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare WorkersPrevention3Not Yet RecruitingNCT04359680
2020-04-30IvermectinNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30NiclosamideNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30FavipiravirNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30ChloroquineNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30EsomeprazoleNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30OseltamivirNovel Coronavirus Infectious Disease (COVID-19)A Real-life Experience on Treatment of Patients With COVID 19Treatment2 / 3Not Yet RecruitingNCT04345419
2020-04-30Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19Treatment2RecruitingNCT04335136
2020-04-30MelphalanNovel Coronavirus Infectious Disease (COVID-19)Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) PneumoniaTreatment2RecruitingNCT04380376
2020-04-30HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?Prevention3Enrolling by InvitationNCT04374942
2020-04-30CanakinumabNovel Coronavirus Infectious Disease (COVID-19)Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaTreatment3RecruitingNCT04362813
2020-04-30LenzilumabNovel Coronavirus Infectious Disease (COVID-19)Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 PneumoniaPrevention3RecruitingNCT04351152
2020-04-30RegramostimNovel Coronavirus Infectious Disease (COVID-19)Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 PneumoniaPrevention3RecruitingNCT04351152
2020-04-30SelinexorNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19Treatment2Not Yet RecruitingNCT04355676
2020-04-30Remestemcel-LNovel Coronavirus Infectious Disease (COVID-19)MSCs in COVID-19 ARDSTreatment3RecruitingNCT04371393
2020-04-30AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-30AmoxicillinNovel Coronavirus Infectious Disease (COVID-19)Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-30Clavulanic acidNovel Coronavirus Infectious Disease (COVID-19)Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-30RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSTreatment2Not Yet RecruitingNCT04374149
2020-04-30ColchicineNovel Coronavirus Infectious Disease (COVID-19)Trial to Study the Benefit of Colchicine in Patients With COVID-19Treatment3RecruitingNCT04350320
2020-04-30AzithromycinNovel Coronavirus Infectious Disease (COVID-19)VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30AzithromycinCOVID-19 PneumoniaAzithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-30AmoxicillinCOVID-19 PneumoniaAzithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-30Clavulanic acidCOVID-19 PneumoniaAzithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive UnitTreatment3Not Yet RecruitingNCT04363060
2020-04-29ChlorpromazineNovel Coronavirus Infectious Disease (COVID-19)Repurposing of Chlorpromazine in Covid-19 TreatmentTreatment3Not Yet RecruitingNCT04366739
2020-04-29KetamineNovel Coronavirus Infectious Disease (COVID-19)Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2RecruitingNCT04365985
2020-04-29NaltrexoneNovel Coronavirus Infectious Disease (COVID-19)Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2RecruitingNCT04365985
2020-04-29Povidone-iodineNovel Coronavirus Infectious Disease (COVID-19)COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and InpatientsPrevention2RecruitingNCT04364802
2020-04-29AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Proactive Care of Ambulatory COVID19 PatientsTreatment3Not Yet RecruitingNCT04371107
2020-04-29HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare SettingPreventionNot AvailableRecruitingNCT04303507
2020-04-29ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare SettingPreventionNot AvailableRecruitingNCT04303507
2020-04-28AzithromycinNovel Coronavirus Infectious Disease (COVID-19)OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor OutcomeTreatment3Not Yet RecruitingNCT04365582
2020-04-28HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor OutcomeTreatment3Not Yet RecruitingNCT04365582
2020-04-28RitonavirNovel Coronavirus Infectious Disease (COVID-19)OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor OutcomeTreatment3Not Yet RecruitingNCT04365582
2020-04-28LopinavirNovel Coronavirus Infectious Disease (COVID-19)OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor OutcomeTreatment3Not Yet RecruitingNCT04365582
2020-04-28DoxycyclineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingTreatment4RecruitingNCT04370782
2020-04-28AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingTreatment4RecruitingNCT04370782
2020-04-28Zinc sulfateNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingTreatment4RecruitingNCT04370782
2020-04-28HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingTreatment4RecruitingNCT04370782
2020-04-28CalcifediolNovel Coronavirus Infectious Disease (COVID-19)Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory SyndromeTreatment2Not Yet RecruitingNCT04366908
2020-04-28HeparinNovel Coronavirus Infectious Disease (COVID-19)Preventing COVID-19 Complications With Low- and High-dose AnticoagulationTreatment3RecruitingNCT04345848
2020-04-28EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)Preventing COVID-19 Complications With Low- and High-dose AnticoagulationTreatment3RecruitingNCT04345848
2020-04-28HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health ProfessionalsPrevention3RecruitingNCT04349228
2020-04-27VerapamilNovel Coronavirus Infectious Disease (COVID-19)Amiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2 / 3RecruitingNCT04351763
2020-04-27AmiodaroneNovel Coronavirus Infectious Disease (COVID-19)Amiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2 / 3RecruitingNCT04351763
2020-04-27LenalidomideNovel Coronavirus Infectious Disease (COVID-19)Low-dose Lenalidomide for Non-severe COVID-19 Treatment TrialTreatment4Not Yet RecruitingNCT04361643
2020-04-27AzithromycinNovel Coronavirus Infectious Disease (COVID-19)A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) PandemicPrevention2RecruitingNCT04369365
2020-04-27ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus DiseaseTreatment2Not Yet RecruitingNCT04367168
2020-04-27TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Tocilizumab on Patients With COVID-19Treatment3Not Yet RecruitingNCT04356937
2020-04-27SarilumabNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial of Sarilumab in Adults With COVID-19Treatment2Not Yet RecruitingNCT04357860
2020-04-27IbuprofenNovel Coronavirus Infectious Disease (COVID-19)LIBERATE Trial in COVID-19Treatment4Not Yet RecruitingNCT04334629
2020-04-27AnakinraNovel Coronavirus Infectious Disease (COVID-19)Anakinra for COVID-19 Respiratory SymptomsTreatment3RecruitingNCT04364009
2020-04-27ProgesteroneNovel Coronavirus Infectious Disease (COVID-19)Progesterone for the Treatment of COVID-19 in Hospitalized MenTreatment1RecruitingNCT04365127
2020-04-27HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)Prevention3RecruitingNCT04363450
2020-04-26ColchicineNovel Coronavirus Infectious Disease (COVID-19)COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19Treatment2RecruitingNCT04363437
2020-04-26TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)Treatment2RecruitingNCT04335071
2020-04-25IvermectinNovel Coronavirus Infectious Disease (COVID-19)Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot StudyTreatmentNot AvailableRecruitingNCT04373824
2020-04-25RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 InfectionNot AvailableNot Yet RecruitingNCT04361903
2020-04-25Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Treatment of Angiotensin Peptide (1-7) for COVID-19TreatmentNot AvailableRecruitingNCT04375124
2020-04-25VazegepantNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTreatment2 / 3RecruitingNCT04346615
2020-04-24HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)HEalth Care Worker pROphylaxis Against COVID-19: The HERO TrialPrevention3Not Yet RecruitingNCT04352946
2020-04-24Peginterferon lambda-1aNovel Coronavirus Infectious Disease (COVID-19)Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19Treatment2RecruitingNCT04331899
2020-04-24CanakinumabNovel Coronavirus Infectious Disease (COVID-19)Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19Treatment2RecruitingNCT04365153
2020-04-24SirolimusNovel Coronavirus Infectious Disease (COVID-19)Sirolimus Treatment in Hospitalized Patients With COVID-19 PneumoniaTreatment2RecruitingNCT04341675
2020-04-24HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19Treatment3Not Yet RecruitingNCT04359953
2020-04-24TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19Treatment3Not Yet RecruitingNCT04359953
2020-04-24AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19Treatment3Not Yet RecruitingNCT04359953
2020-04-24SirukumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19Treatment2RecruitingNCT04380961
2020-04-24BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19Treatment2RecruitingNCT04373044
2020-04-24HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19Treatment2RecruitingNCT04373044
2020-04-23HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19Treatment0SuspendedNCT04329572
2020-04-23AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19Treatment0SuspendedNCT04329572
2020-04-23OlokizumabNovel Coronavirus Infectious Disease (COVID-19)Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)Treatment2 / 3RecruitingNCT04380519
2020-04-23LopinavirNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1 / 2RecruitingNCT04366245
2020-04-23AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1 / 2RecruitingNCT04366245
2020-04-23HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1 / 2RecruitingNCT04366245
2020-04-23RitonavirNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1 / 2RecruitingNCT04366245
2020-04-23AcetaminophenNovel Coronavirus Infectious Disease (COVID-19)A Study of a Candidate COVID-19 Vaccine (COV001)Treatment1 / 2Active Not RecruitingNCT04324606
2020-04-23AZD1222Novel Coronavirus Infectious Disease (COVID-19)A Study of a Candidate COVID-19 Vaccine (COV001)Treatment1 / 2Active Not RecruitingNCT04324606
2020-04-23SevofluraneNovel Coronavirus Infectious Disease (COVID-19)Sevoflurane in COVID-19 ARDS (SevCov)Treatment3RecruitingNCT04355962
2020-04-22RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Ruxolitinib in Covid-19 Patients With Defined HyperinflammationTreatment2RecruitingNCT04338958
2020-04-22AlteplaseNovel Coronavirus Infectious Disease (COVID-19)Nebulised Rt-PA for ARDS Due to COVID-19Treatment2RecruitingNCT04356833
2020-04-22HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine for the Treatment of Mild COVID-19 DiseaseTreatment3RecruitingNCT04340544
2020-04-22HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Healthcare Worker Exposure Response and Outcomes of HydroxychloroquinePrevention3RecruitingNCT04334148
2020-04-21IsotretinoinNovel Coronavirus Infectious Disease (COVID-19)Isotretinoin in Treatment of COVID-19Treatment3Not Yet RecruitingNCT04361422
2020-04-21HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Test and Treat COVID 65plus+Treatment2 / 3RecruitingNCT04351516
2020-04-21SpironolactoneNovel Coronavirus Infectious Disease (COVID-19)Spironolactone in Covid-19 Induced ARDSTreatment4Not Yet RecruitingNCT04345887
2020-04-21BudesonideNovel Coronavirus Infectious Disease (COVID-19)Inhaled Corticosteroid Treatment of COVID19 Patients With PneumoniaTreatment4RecruitingNCT04355637
2020-04-21AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialTreatment3RecruitingNCT04324463
2020-04-21ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialTreatment3RecruitingNCT04324463
2020-04-21Human interferon betaNovel Coronavirus Infectious Disease (COVID-19)Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialTreatment3RecruitingNCT04324463
2020-04-21MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21HeparinNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21LopinavirNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21RitonavirNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21PiperacillinNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21TazobactamNovel Coronavirus Infectious Disease (COVID-19)Ultra Low Doses of Therapy With Radiation Applicated to COVID-19Supportive CareNot AvailableRecruitingNCT04394182
2020-04-21ClazakizumabNovel Coronavirus Infectious Disease (COVID-19)Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 DiseaseTreatment2Not Yet RecruitingNCT04348500
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled TrialTreatment3Not Yet RecruitingNCT04339816
2020-04-20AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled TrialTreatment3Not Yet RecruitingNCT04339816
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Preventing COVID-19 in Healthcare Workers With HCQ: A RCTPrevention2Not Yet RecruitingNCT04347889
2020-04-20AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19Treatment0SuspendedNCT04348474
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19Treatment0SuspendedNCT04348474
2020-04-20AnakinraNovel Coronavirus Infectious Disease (COVID-19)Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsNot AvailableRecruitingNCT04362943
2020-04-20BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsNot AvailableRecruitingNCT04362943
2020-04-20AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Azithromycin in Hospitalized COVID-19 PatientsTreatment4Not Yet RecruitingNCT04359316
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Azithromycin in Hospitalized COVID-19 PatientsTreatment4Not Yet RecruitingNCT04359316
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Favipiravir in Hospitalized COVID-19 PatientsTreatment4Not Yet RecruitingNCT04359615
2020-04-20FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Favipiravir in Hospitalized COVID-19 PatientsTreatment4Not Yet RecruitingNCT04359615
2020-04-20BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04345289
2020-04-20SarilumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04345289
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 PneumoniaTreatment3Not Yet RecruitingNCT04345289
2020-04-20BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19Prevention3Not Yet RecruitingNCT04350931
2020-04-20FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Favipiravir in Management of COVID-19Treatment3Not Yet RecruitingNCT04349241
2020-04-20PyrazinamideNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Favipiravir in Management of COVID-19Treatment3Not Yet RecruitingNCT04349241
2020-04-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19Prevention3Not Yet RecruitingNCT04346329
2020-04-20EstradiolNovel Coronavirus Infectious Disease (COVID-19)Estrogen Patch for COVID-19 SymptomsTreatment2RecruitingNCT04359329
2020-04-20BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)BCG Vaccine for Health Care Workers as Defense Against COVID 19Prevention4RecruitingNCT04348370
2020-04-20ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine Counteracting Inflammation in COVID-19 PneumoniaTreatment2RecruitingNCT04322565
2020-04-20HeparinNovel Coronavirus Infectious Disease (COVID-19)Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 CohortTreatment2Not Yet RecruitingNCT04344756
2020-04-20TinzaparinNovel Coronavirus Infectious Disease (COVID-19)Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 CohortTreatment2Not Yet RecruitingNCT04344756
2020-04-20AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Atovaquone and Azithromycin Combination for Confirmed COVID-19 InfectionTreatment2RecruitingNCT04339426
2020-04-20AtovaquoneNovel Coronavirus Infectious Disease (COVID-19)Atovaquone and Azithromycin Combination for Confirmed COVID-19 InfectionTreatment2RecruitingNCT04339426
2020-04-20DexmedetomidineNovel Coronavirus Infectious Disease (COVID-19)Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 InfectionTreatment4Not Yet RecruitingNCT04350086
2020-04-19Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Clinical Application of Methylene Blue for Treatment of Covid-19 PatientsTreatment1RecruitingNCT04370288
2020-04-19CysteineNovel Coronavirus Infectious Disease (COVID-19)Clinical Application of Methylene Blue for Treatment of Covid-19 PatientsTreatment1RecruitingNCT04370288
2020-04-19Methylene blueNovel Coronavirus Infectious Disease (COVID-19)Clinical Application of Methylene Blue for Treatment of Covid-19 PatientsTreatment1RecruitingNCT04370288
2020-04-18ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine in COVID-19: a Pilot StudyTreatment2RecruitingNCT04375202
2020-04-18LactoseNovel Coronavirus Infectious Disease (COVID-19)Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 PatientsTreatment1RecruitingNCT04343092
2020-04-18AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 PatientsTreatment1RecruitingNCT04343092
2020-04-18HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 PatientsTreatment1RecruitingNCT04343092
2020-04-18IvermectinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 PatientsTreatment1RecruitingNCT04343092
2020-04-18MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19Treatment2RecruitingNCT04343729
2020-04-18Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Inhalation Therapy for COVID-19 Infections in the EDTreatment2RecruitingNCT04338828
2020-04-17ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacay of Chloroquine in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04353336
2020-04-17FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19Treatment2RecruitingNCT04358549
2020-04-17ColchicineNovel Coronavirus Infectious Disease (COVID-19)The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.Treatment3RecruitingNCT04328480
2020-04-17IvermectinNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04351347
2020-04-17EsomeprazoleNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04351347
2020-04-17NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04351347
2020-04-17ChloroquineNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04351347
2020-04-17FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Faviprevir in COVID-19 TreatmentTreatment2 / 3Not Yet RecruitingNCT04351295
2020-04-17Hydrocortisone succinateNovel Coronavirus Infectious Disease (COVID-19)Hydrocortisone for COVID-19 and Severe HypoxiaTreatment3RecruitingNCT04348305
2020-04-17HydrocortisoneNovel Coronavirus Infectious Disease (COVID-19)Hydrocortisone for COVID-19 and Severe HypoxiaTreatment3RecruitingNCT04348305
2020-04-17Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)Hydrocortisone for COVID-19 and Severe HypoxiaTreatment3RecruitingNCT04348305
2020-04-17BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsTreatment2RecruitingNCT04321993
2020-04-17HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsTreatment2RecruitingNCT04321993
2020-04-17RitonavirNovel Coronavirus Infectious Disease (COVID-19)Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsTreatment2RecruitingNCT04321993
2020-04-17LopinavirNovel Coronavirus Infectious Disease (COVID-19)Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsTreatment2RecruitingNCT04321993
2020-04-17SelinexorNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 InfectionTreatment2RecruitingNCT04349098
2020-04-17HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Trial of Hydroxychloroquine In Covid-19 KineticsTreatment2 / 3Active Not RecruitingNCT04353271
2020-04-17LopinavirNovel Coronavirus Infectious Disease (COVID-19)COVID-19 Ring-based Prevention Trial With Lopinavir/RitonavirPrevention3RecruitingNCT04321174
2020-04-17RitonavirNovel Coronavirus Infectious Disease (COVID-19)COVID-19 Ring-based Prevention Trial With Lopinavir/RitonavirPrevention3RecruitingNCT04321174
2020-04-17AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 InfectionTreatment2RecruitingNCT04335552
2020-04-17HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 InfectionTreatment2RecruitingNCT04335552
2020-04-17ValsartanNovel Coronavirus Infectious Disease (COVID-19)Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection DiseaseTreatment4RecruitingNCT04335786
2020-04-16Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased OxygenationTreatment1 / 2RecruitingNCT04357782
2020-04-16TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With TocilizumabNot AvailableRecruitingNCT04359667
2020-04-16EnoxaparinNovel Coronavirus Infectious Disease (COVID-19)A Randomized Trial of Anticoagulation Strategies in COVID-19Treatment3RecruitingNCT04359277
2020-04-16HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16RivaroxabanNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16CandesartanNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16LopinavirNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16RitonavirNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16ClazakizumabNovel Coronavirus Infectious Disease (COVID-19)Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Treatment2 / 3RecruitingNCT04351724
2020-04-16HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19Treatment1 / 2RecruitingNCT04344457
2020-04-16IndomethacinNovel Coronavirus Infectious Disease (COVID-19)Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19Treatment1 / 2RecruitingNCT04344457
2020-04-16AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19Treatment1 / 2RecruitingNCT04344457
2020-04-16ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine as Antiviral Treatment in Coronavirus Infection 2020Treatment4RecruitingNCT04331600
2020-04-16CyclosporineNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19Treatment4RecruitingNCT04392531
2020-04-16SevofluraneNovel Coronavirus Infectious Disease (COVID-19)Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 InfectionTreatment4RecruitingNCT04359862
2020-04-16PropofolNovel Coronavirus Infectious Disease (COVID-19)Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 InfectionTreatment4RecruitingNCT04359862
2020-04-16EculizumabNovel Coronavirus Infectious Disease (COVID-19)CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 CohortTreatment2RecruitingNCT04346797
2020-04-16Folic acidNovel Coronavirus Infectious Disease (COVID-19)Treatment for COVID-19 in High-Risk Adult OutpatientsTreatment2 / 3RecruitingNCT04354428
2020-04-16Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Treatment for COVID-19 in High-Risk Adult OutpatientsTreatment2 / 3RecruitingNCT04354428
2020-04-16AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Treatment for COVID-19 in High-Risk Adult OutpatientsTreatment2 / 3RecruitingNCT04354428
2020-04-16HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treatment for COVID-19 in High-Risk Adult OutpatientsTreatment2 / 3RecruitingNCT04354428
2020-04-15MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of ProgressionTreatment3Not Yet RecruitingNCT04345445
2020-04-15TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of ProgressionTreatment3Not Yet RecruitingNCT04345445
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Umifenovir in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350684
2020-04-15UmifenovirNovel Coronavirus Infectious Disease (COVID-19)Umifenovir in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350684
2020-04-15RitonavirNovel Coronavirus Infectious Disease (COVID-19)Umifenovir in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350684
2020-04-15LopinavirNovel Coronavirus Infectious Disease (COVID-19)Umifenovir in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350684
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Interferon Beta 1a in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350671
2020-04-15RitonavirNovel Coronavirus Infectious Disease (COVID-19)Interferon Beta 1a in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350671
2020-04-15LopinavirNovel Coronavirus Infectious Disease (COVID-19)Interferon Beta 1a in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350671
2020-04-15Interferon beta-1aNovel Coronavirus Infectious Disease (COVID-19)Interferon Beta 1a in Hospitalized COVID-19 PatientsTreatment4Enrolling by InvitationNCT04350671
2020-04-15DapagliflozinNovel Coronavirus Infectious Disease (COVID-19)Dapagliflozin in Respiratory Failure in Patients With COVID-19Treatment3RecruitingNCT04350593
2020-04-15SiltuximabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 PneumoniaTreatment2RecruitingNCT04329650
2020-04-15MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 PneumoniaTreatment2RecruitingNCT04329650
2020-04-15RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Treatment of SARS Caused by COVID-19 With RuxolitinibTreatment1 / 2RecruitingNCT04334044
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treating COVID-19 With Hydroxychloroquine (TEACH)Treatment2RecruitingNCT04369742
2020-04-15AnakinraNovel Coronavirus Infectious Disease (COVID-19)suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)Prevention2RecruitingNCT04357366
2020-04-15TrimethoprimNovel Coronavirus Infectious Disease (COVID-19)suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)Prevention2RecruitingNCT04357366
2020-04-15SulfamethoxazoleNovel Coronavirus Infectious Disease (COVID-19)suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)Prevention2RecruitingNCT04357366
2020-04-15EnalaprilNovel Coronavirus Infectious Disease (COVID-19)Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19Treatment3Not Yet RecruitingNCT04345406
2020-04-15CaptoprilNovel Coronavirus Infectious Disease (COVID-19)Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19Treatment3Not Yet RecruitingNCT04345406
2020-04-15ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19Treatment3Not Yet RecruitingNCT04345406
2020-04-15Dornase alfaNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)Treatment3RecruitingNCT04355364
2020-04-15IvermectinNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Ivermectin in COVID-19TreatmentNot AvailableRecruitingNCT04392713
2020-04-15ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 InfectionTreatment2RecruitingNCT04333914
2020-04-15TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 InfectionTreatment2RecruitingNCT04333914
2020-04-15NivolumabNovel Coronavirus Infectious Disease (COVID-19)Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 InfectionTreatment2RecruitingNCT04333914
2020-04-15CholecalciferolNovel Coronavirus Infectious Disease (COVID-19)COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)Treatment3RecruitingNCT04344041
2020-04-15BevacizumabNovel Coronavirus Infectious Disease (COVID-19)Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 CohortTreatment2Not Yet RecruitingNCT04344782
2020-04-15EmtricitabineNovel Coronavirus Infectious Disease (COVID-19)Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare PersonnelPrevention3RecruitingNCT04334928
2020-04-15Tenofovir disoproxilNovel Coronavirus Infectious Disease (COVID-19)Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare PersonnelPrevention3RecruitingNCT04334928
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare PersonnelPrevention3RecruitingNCT04334928
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the VirusPrevention3RecruitingNCT04344379
2020-04-15AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the VirusPrevention3RecruitingNCT04344379
2020-04-15NivolumabNovel Coronavirus Infectious Disease (COVID-19)Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.Treatment2Not Yet RecruitingNCT04343144
2020-04-15DexmedetomidineNovel Coronavirus Infectious Disease (COVID-19)Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 PatientsNot AvailableNot Yet RecruitingNCT04358627
2020-04-15TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)Treatment3Not Yet RecruitingNCT04356495
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)Treatment3Not Yet RecruitingNCT04356495
2020-04-15ImatinibNovel Coronavirus Infectious Disease (COVID-19)Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)Treatment3Not Yet RecruitingNCT04356495
2020-04-15FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)Treatment3Not Yet RecruitingNCT04356495
2020-04-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE CompoundsTreatment4RecruitingNCT04351191
2020-04-15ChloroquineNovel Coronavirus Infectious Disease (COVID-19)PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE CompoundsTreatment4RecruitingNCT04351191
2020-04-15Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Stopping ACE-inhibitors in COVID-19Treatment4RecruitingNCT04353596
2020-04-15LeronlimabNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)Treatment2RecruitingNCT04347239
2020-04-14MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Prophylactic Corticosteroid to Prevent COVID-19 Cytokine StormPrevention2RecruitingNCT04355247
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)Treatment3RecruitingNCT04315896
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)Prevention3RecruitingNCT04318015
2020-04-14ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19Treatment4RecruitingNCT04362332
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19Treatment4RecruitingNCT04362332
2020-04-14RitonavirNovel Coronavirus Infectious Disease (COVID-19)Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersPrevention3RecruitingNCT04328285
2020-04-14LopinavirNovel Coronavirus Infectious Disease (COVID-19)Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersPrevention3RecruitingNCT04328285
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersPrevention3RecruitingNCT04328285
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)University of Utah COVID-19 Hydrochloroquine TrialTreatment2RecruitingNCT04342169
2020-04-14CalcifediolNovel Coronavirus Infectious Disease (COVID-19)Oral 25-hydroxyvitamin D3 and COVID-19Prevention2 / 3RecruitingNCT04386850
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare WorkersPrevention2Enrolling by InvitationNCT04345653
2020-04-14AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Qatar Prospective RCT Of Therapy Eliminating Covid TransmissionTreatmentNot AvailableNot Yet RecruitingNCT04349592
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Qatar Prospective RCT Of Therapy Eliminating Covid TransmissionTreatmentNot AvailableNot Yet RecruitingNCT04349592
2020-04-14NivolumabNovel Coronavirus Infectious Disease (COVID-19)COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1Treatment2Not Yet RecruitingNCT04356508
2020-04-14HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE CompoundsTreatment4RecruitingNCT04346667
2020-04-14ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE CompoundsTreatment4RecruitingNCT04346667
2020-04-13SarilumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)Treatment2RecruitingNCT04357808
2020-04-13HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 DiseaseTreatment3RecruitingNCT04329611
2020-04-13BudesonideNovel Coronavirus Infectious Disease (COVID-19)Protective Role of Inhaled Steroids for Covid-19 InfectionTreatment3RecruitingNCT04331054
2020-04-13FormoterolNovel Coronavirus Infectious Disease (COVID-19)Protective Role of Inhaled Steroids for Covid-19 InfectionTreatment3RecruitingNCT04331054
2020-04-13LopinavirNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13RitonavirNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13ImatinibNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13TradipitantNovel Coronavirus Infectious Disease (COVID-19)ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionTreatment3Enrolling by InvitationNCT04326426
2020-04-13LosartanNovel Coronavirus Infectious Disease (COVID-19)Losartan for Patients With COVID-19 Requiring HospitalizationTreatment2RecruitingNCT04312009
2020-04-13IcosapentNovel Coronavirus Infectious Disease (COVID-19)EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)Treatment3Not Yet RecruitingNCT04335032
2020-04-13LopinavirCOVID-19 PneumoniaClinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13RitonavirCOVID-19 PneumoniaClinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13BaricitinibCOVID-19 PneumoniaClinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13ImatinibCOVID-19 PneumoniaClinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-13HydroxychloroquineCOVID-19 PneumoniaClinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Treatment2RecruitingNCT04346147
2020-04-12NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19TreatmentNot AvailableRecruitingNCT04348409
2020-04-12Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving AntihypertensivesNot AvailableTerminatedNCT04357535
2020-04-12Ad5-nCoVNovel Coronavirus Infectious Disease (COVID-19)A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)Prevention2Active Not RecruitingNCT04341389
2020-04-12HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in Outpatient Adults With COVID-19Treatment1RecruitingNCT04333654
2020-04-12RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Treatment2RecruitingNCT04348695
2020-04-12SimvastatinNovel Coronavirus Infectious Disease (COVID-19)Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Treatment2RecruitingNCT04348695
2020-04-12GimsilumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.Treatment2RecruitingNCT04351243
2020-04-11Sodium chlorideNovel Coronavirus Infectious Disease (COVID-19)Polyvalent Immunoglobulin in COVID-19 Related ARdsTreatment3RecruitingNCT04350580
2020-04-11CamostatNovel Coronavirus Infectious Disease (COVID-19)Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 VirusTreatment3RecruitingNCT04355052
2020-04-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 VirusTreatment3RecruitingNCT04355052
2020-04-11AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 VirusTreatment3RecruitingNCT04355052
2020-04-11TocilizumabNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11AzithromycinNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11LosartanNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11RemdesivirNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11DoxycyclineNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11PrimaquineNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11ClindamycinNovel Coronavirus Infectious Disease (COVID-19)The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2 / 3Enrolling by InvitationNCT04349410
2020-04-11AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)Treatment2 / 3RecruitingNCT04345861
2020-04-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)Treatment2 / 3RecruitingNCT04345861
2020-04-11SarilumabNovel Coronavirus Infectious Disease (COVID-19)Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIROTreatment2 / 3SuspendedNCT04341870
2020-04-11AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIROTreatment2 / 3SuspendedNCT04341870
2020-04-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIROTreatment2 / 3SuspendedNCT04341870
2020-04-10AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe DiseaseTreatment3RecruitingNCT04344444
2020-04-10HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe DiseaseTreatment3RecruitingNCT04344444
2020-04-10DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 PneumoniaTreatmentNot AvailableRecruitingNCT04344730
2020-04-10HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 PneumoniaTreatment4RecruitingNCT04355026
2020-04-10BromhexineNovel Coronavirus Infectious Disease (COVID-19)Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 PneumoniaTreatment4RecruitingNCT04355026
2020-04-10SarilumabNovel Coronavirus Infectious Disease (COVID-19)Sarilumab for Patients With Moderate COVID-19 DiseaseTreatment2SuspendedNCT04359901
2020-04-10FluvoxamineNovel Coronavirus Infectious Disease (COVID-19)A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 InfectionTreatment2RecruitingNCT04342663
2020-04-10TofacitinibNovel Coronavirus Infectious Disease (COVID-19)TOFAcitinib in SARS-CoV2 PneumoniaTreatment2Not Yet RecruitingNCT04332042
2020-04-10EIDD-2801Novel Coronavirus Infectious Disease (COVID-19)COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy VolunteersTreatment1RecruitingNCT04392219
2020-04-09PovidoneNovel Coronavirus Infectious Disease (COVID-19)Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19Treatment2RecruitingNCT04344236
2020-04-09IodineNovel Coronavirus Infectious Disease (COVID-19)Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19Treatment2RecruitingNCT04344236
2020-04-09ChlorhexidineNovel Coronavirus Infectious Disease (COVID-19)Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19Treatment2RecruitingNCT04344236
2020-04-09HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)Treatment2RecruitingNCT04329923
2020-04-09Interferon beta-1bNovel Coronavirus Infectious Disease (COVID-19)Double Therapy With IFN-beta 1b and HydroxychloroquineTreatment2RecruitingNCT04350281
2020-04-09HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Double Therapy With IFN-beta 1b and HydroxychloroquineTreatment2RecruitingNCT04350281
2020-04-09HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialTreatment2CompletedNCT04343768
2020-04-09Interferon beta-1bNovel Coronavirus Infectious Disease (COVID-19)An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialTreatment2CompletedNCT04343768
2020-04-09Interferon beta-1aNovel Coronavirus Infectious Disease (COVID-19)An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialTreatment2CompletedNCT04343768
2020-04-09LopinavirNovel Coronavirus Infectious Disease (COVID-19)An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialTreatment2CompletedNCT04343768
2020-04-09RitonavirNovel Coronavirus Infectious Disease (COVID-19)An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialTreatment2CompletedNCT04343768
2020-04-09LosartanNovel Coronavirus Infectious Disease (COVID-19)Losartan for Patients With COVID-19 Not Requiring HospitalizationTreatment2RecruitingNCT04311177
2020-04-08ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine Diphosphate in the Prevention of SARS in Covid-19 InfectionTreatment2RecruitingNCT04342650
2020-04-08AT-001Novel Coronavirus Infectious Disease (COVID-19)Cardiovascular Effects of COVID-19Treatment2RecruitingNCT04365699
2020-04-08HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19Treatment2Enrolling by InvitationNCT04347031
2020-04-08TocilizumabNovel Coronavirus Infectious Disease (COVID-19)An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19Treatment2Enrolling by InvitationNCT04347031
2020-04-08AzithromycinNovel Coronavirus Infectious Disease (COVID-19)An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19Treatment2Enrolling by InvitationNCT04347031
2020-04-08MefloquineNovel Coronavirus Infectious Disease (COVID-19)An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19Treatment2Enrolling by InvitationNCT04347031
2020-04-08Human immunoglobulin GNovel Coronavirus Infectious Disease (COVID-19)CD24Fc as a Non-antiviral Immunomodulator in COVID-19 TreatmentTreatment3RecruitingNCT04317040
2020-04-08TocilizumabNovel Coronavirus Infectious Disease (COVID-19)The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary HyperinflammationTreatment4RecruitingNCT04377750
2020-04-08DefibrotideNovel Coronavirus Infectious Disease (COVID-19)Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.Treatment2RecruitingNCT04348383
2020-04-08Human immunoglobulin GSevere Coronavirus Disease (COVID-19)CD24Fc as a Non-antiviral Immunomodulator in COVID-19 TreatmentTreatment3RecruitingNCT04317040
2020-04-07ChloroquineNovel Coronavirus Infectious Disease (COVID-19)The Vietnam Chloroquine Treatment on COVID-19Treatment2RecruitingNCT04328493
2020-04-07FamotidineNovel Coronavirus Infectious Disease (COVID-19)Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19Treatment3RecruitingNCT04370262
2020-04-07HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Will Hydroxychloroquine Impede or Prevent COVID-19Prevention3RecruitingNCT04341441
2020-04-07HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCTTreatment3Not Yet RecruitingNCT04338698
2020-04-07OseltamivirNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCTTreatment3Not Yet RecruitingNCT04338698
2020-04-07AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCTTreatment3Not Yet RecruitingNCT04338698
2020-04-06RuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 PneumoniaTreatmentNot AvailableNot Yet RecruitingNCT04331665
2020-04-06PiclidenosonNovel Coronavirus Infectious Disease (COVID-19)Piclidenoson for Treatment of COVID-19Treatment2Not Yet RecruitingNCT04333472
2020-04-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Pre-exposure Prophylaxis for SARS-Coronavirus-2Treatment3RecruitingNCT04328467
2020-04-06ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical TrialPrevention2RecruitingNCT04344951
2020-04-06RitonavirNovel Coronavirus Infectious Disease (COVID-19)COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2Treatment2 / 3RecruitingNCT04328012
2020-04-06LopinavirNovel Coronavirus Infectious Disease (COVID-19)COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2Treatment2 / 3RecruitingNCT04328012
2020-04-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2Treatment2 / 3RecruitingNCT04328012
2020-04-06LosartanNovel Coronavirus Infectious Disease (COVID-19)COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2Treatment2 / 3RecruitingNCT04328012
2020-04-06NitazoxanideNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19Treatment4RecruitingNCT04341493
2020-04-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19Treatment4RecruitingNCT04341493
2020-04-06AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19Treatment2RecruitingNCT04322396
2020-04-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19Treatment2RecruitingNCT04322396
2020-04-06DefibrotideNovel Coronavirus Infectious Disease (COVID-19)Defibrotide in COVID-19 PneumoniaTreatment2Not Yet RecruitingNCT04335201
2020-04-06Acetylsalicylic acidNovel Coronavirus Infectious Disease (COVID-19)Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19Treatment2CompletedNCT04368377
2020-04-06FondaparinuxNovel Coronavirus Infectious Disease (COVID-19)Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19Treatment2CompletedNCT04368377
2020-04-06TirofibanNovel Coronavirus Infectious Disease (COVID-19)Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19Treatment2CompletedNCT04368377
2020-04-06ClopidogrelNovel Coronavirus Infectious Disease (COVID-19)Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19Treatment2CompletedNCT04368377
2020-04-05SarilumabNovel Coronavirus Infectious Disease (COVID-19)Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory FailureTreatment2RecruitingNCT04322773
2020-04-05TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory FailureTreatment2RecruitingNCT04322773
2020-04-04TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 PneumonitisTreatment2RecruitingNCT04331795
2020-04-04CamostatNovel Coronavirus Infectious Disease (COVID-19)The Impact of Camostat Mesilate on COVID-19 InfectionTreatment1 / 2RecruitingNCT04321096
2020-04-04HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 InfectionTreatment3RecruitingNCT04341727
2020-04-04AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 InfectionTreatment3RecruitingNCT04341727
2020-04-04ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 InfectionTreatment3RecruitingNCT04341727
2020-04-04PyridostigmineNovel Coronavirus Infectious Disease (COVID-19)Pyridostigmine in Severe SARS-CoV-2 InfectionTreatment2 / 3RecruitingNCT04343963
2020-04-03HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 PandemicPrevention3RecruitingNCT04331834
2020-04-03AtorvastatinNovel Coronavirus Infectious Disease (COVID-19)Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TreatmentNot AvailableRecruitingNCT04333407
2020-04-03RivaroxabanNovel Coronavirus Infectious Disease (COVID-19)Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TreatmentNot AvailableRecruitingNCT04333407
2020-04-03OmeprazoleNovel Coronavirus Infectious Disease (COVID-19)Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TreatmentNot AvailableRecruitingNCT04333407
2020-04-03Acetylsalicylic acidNovel Coronavirus Infectious Disease (COVID-19)Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TreatmentNot AvailableRecruitingNCT04333407
2020-04-03ClopidogrelNovel Coronavirus Infectious Disease (COVID-19)Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TreatmentNot AvailableRecruitingNCT04333407
2020-04-03HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)COVID-19 PrEP HCW HCQ StudyTreatment2RecruitingNCT04354870
2020-04-03HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare WorkersPrevention2Active Not RecruitingNCT04333225
2020-04-03TocilizumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 PneumoniaTreatment3RecruitingNCT04320615
2020-04-03ColchicineNovel Coronavirus Infectious Disease (COVID-19)The GReek Study in the Effects of Colchicine in Covid-19 cOmplications PreventionTreatment2RecruitingNCT04326790
2020-04-03AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer PatientsTreatment2RecruitingNCT04341207
2020-04-03HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer PatientsTreatment2RecruitingNCT04341207
2020-04-03DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19Treatment4RecruitingNCT04325061
2020-04-03TocilizumabCOVID-19 PneumoniaA Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 PneumoniaTreatment3RecruitingNCT04320615
2020-04-02HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19Treatment2RecruitingNCT04332094
2020-04-02TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19Treatment2RecruitingNCT04332094
2020-04-02AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19Treatment2RecruitingNCT04332094
2020-04-02NintedanibNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19Treatment2Not Yet RecruitingNCT04338802
2020-04-02AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19Treatment3RecruitingNCT04334382
2020-04-02HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19Treatment3RecruitingNCT04334382
2020-04-02AnakinraNovel Coronavirus Infectious Disease (COVID-19)Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ DysfunctionTreatment2RecruitingNCT04339712
2020-04-02TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ DysfunctionTreatment2RecruitingNCT04339712
2020-04-02HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic DiseaseTreatment3RecruitingNCT04332991
2020-04-02Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)NO Prevention of COVID-19 for Healthcare ProvidersPrevention2Not Yet RecruitingNCT04312243
2020-04-02EmapalumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.Treatment2 / 3RecruitingNCT04324021
2020-04-02AnakinraNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.Treatment2 / 3RecruitingNCT04324021
2020-04-01CiclesonideNovel Coronavirus Infectious Disease (COVID-19)A Trial of Ciclesonide in Adults With Mild COVID-19Treatment2Not Yet RecruitingNCT04330586
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Trial of Ciclesonide in Adults With Mild COVID-19Treatment2Not Yet RecruitingNCT04330586
2020-04-01ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine for Mild Symptomatic and Asymptomatic COVID-19Treatment2 / 3Not Yet RecruitingNCT04333628
2020-04-01MavrilimumabNovel Coronavirus Infectious Disease (COVID-19)Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Not Yet RecruitingNCT04337216
2020-04-01CanakinumabNovel Coronavirus Infectious Disease (COVID-19)Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 PneumoniaNot AvailableNot Yet RecruitingNCT04348448
2020-04-01Chlorine DioxideNovel Coronavirus Infectious Disease (COVID-19)Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19Not AvailableRecruitingNCT04343742
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis StudyPrevention2Not Yet RecruitingNCT04343677
2020-04-01TacrolimusNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung InjuryTreatment3RecruitingNCT04341038
2020-04-01MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung InjuryTreatment3RecruitingNCT04341038
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19Treatment1RecruitingNCT04351620
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19Treatment3RecruitingNCT04347980
2020-04-01DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19Treatment3RecruitingNCT04347980
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at MontefioreTreatment2Not Yet RecruitingNCT04350450
2020-04-01PrednisoneNovel Coronavirus Infectious Disease (COVID-19)Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 InfectionTreatment2RecruitingNCT04344288
2020-04-01LosartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus Response - Active Support for Hospitalised Covid-19 PatientsTreatment3Not Yet RecruitingNCT04343001
2020-04-01SimvastatinNovel Coronavirus Infectious Disease (COVID-19)Coronavirus Response - Active Support for Hospitalised Covid-19 PatientsTreatment3Not Yet RecruitingNCT04343001
2020-04-01Acetylsalicylic acidNovel Coronavirus Infectious Disease (COVID-19)Coronavirus Response - Active Support for Hospitalised Covid-19 PatientsTreatment3Not Yet RecruitingNCT04343001
2020-04-01RamiprilNovel Coronavirus Infectious Disease (COVID-19)Ramipril for the Treatment of COVID-19Treatment2Not Yet RecruitingNCT04366050
2020-04-01Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)ARB, ACEi, DRi in COVID-19Not AvailableRecruitingNCT04364984
2020-04-01TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Treatment of COVID-19 Patients With Anti-interleukin DrugsTreatment3RecruitingNCT04330638
2020-04-01AnakinraNovel Coronavirus Infectious Disease (COVID-19)Treatment of COVID-19 Patients With Anti-interleukin DrugsTreatment3RecruitingNCT04330638
2020-04-01SiltuximabNovel Coronavirus Infectious Disease (COVID-19)Treatment of COVID-19 Patients With Anti-interleukin DrugsTreatment3RecruitingNCT04330638
2020-04-01FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to PositiveTreatmentNot AvailableRecruitingNCT04333589
2020-04-01ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Saved From COVID-19Prevention2RecruitingNCT04349371
2020-04-01DeferoxamineNovel Coronavirus Infectious Disease (COVID-19)Application of Desferal to Treat COVID-19Treatment1 / 2RecruitingNCT04333550
2020-04-01ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine Plus Phenolic Monoterpenes to Treat COVID-19Treatment1 / 2RecruitingNCT04392141
2020-04-01AnakinraNovel Coronavirus Infectious Disease (COVID-19)CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 InfectionTreatment2Not Yet RecruitingNCT04341584
2020-04-01DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil IIITreatment3Not Yet RecruitingNCT04327401
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe DiseaseTreatment3RecruitingNCT04325893
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)Prevention3Not Yet RecruitingNCT04330144
2020-04-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)Treatment3Active Not RecruitingNCT04322123
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)Treatment3Active Not RecruitingNCT04322123
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19Prevention3Not Yet RecruitingNCT04342156
2020-04-01DAS-181Novel Coronavirus Infectious Disease (COVID-19)DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)Treatment2Not Yet RecruitingNCT04298060
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19Treatment4RecruitingNCT04384380
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in SwitzerlandPrevention3RecruitingNCT04364022
2020-04-01RitonavirNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in SwitzerlandPrevention3RecruitingNCT04364022
2020-04-01LopinavirNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in SwitzerlandPrevention3RecruitingNCT04364022
2020-04-01RibavirinNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19Treatment1Not Yet RecruitingNCT04356677
2020-04-01NafamostatNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)Treatment2 / 3Not Yet RecruitingNCT04352400
2020-04-01MelatoninNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.Prevention2 / 3Not Yet RecruitingNCT04353128
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Azithromycin COVID-19 Pregnancy TrialTreatment3Not Yet RecruitingNCT04365231
2020-04-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Azithromycin COVID-19 Pregnancy TrialTreatment3Not Yet RecruitingNCT04365231
2020-04-01Sodium bicarbonateNovel Coronavirus Infectious Disease (COVID-19)Inhalable Sodium Bicarbonate: A Possible Adjuvant Treatment of Patients With Novel COVID-19Treatment0Active Not RecruitingNCT04374591
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)HCQ for Primary Prophylaxis Against COVID19 in Health-care WorkersPrevention3Not Yet RecruitingNCT04336748
2020-04-01TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab Treatment in Patients With COVID-19Treatment2RecruitingNCT04363853
2020-04-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19Treatment2RecruitingNCT04336332
2020-04-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19Treatment2RecruitingNCT04336332
2020-04-01LeronlimabNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19Treatment2RecruitingNCT04343651
2020-03-31MemantineNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31RitonavirNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31LopinavirNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31LevamisoleNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31BudesonideNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31FormoterolNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19Treatment2 / 3Not Yet RecruitingNCT04331470
2020-03-31ClazakizumabNovel Coronavirus Infectious Disease (COVID-19)A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2RecruitingNCT04343989
2020-03-31SalbutamolNovel Coronavirus Infectious Disease (COVID-19)Dornase Alfa Administered to Patients With COVID-19 (DACOVID)Not AvailableActive Not RecruitingNCT04387786
2020-03-31Dornase alfaNovel Coronavirus Infectious Disease (COVID-19)Dornase Alfa Administered to Patients With COVID-19 (DACOVID)Not AvailableActive Not RecruitingNCT04387786
2020-03-31TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Early Administration of Tocilizumab in COVID-19 PatientsTreatment2RecruitingNCT04346355
2020-03-31Angiotensin 1-7Novel Coronavirus Infectious Disease (COVID-19)Angiotensin-(1,7) Treatment in COVID-19: the ATCO TrialTreatment2 / 3Not Yet RecruitingNCT04332666
2020-03-31HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)Prevention2 / 3RecruitingNCT04328961
2020-03-31Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)Prevention2 / 3RecruitingNCT04328961
2020-03-31TocilizumabCOVID-19 PneumoniaEfficacy of Early Administration of Tocilizumab in COVID-19 PatientsTreatment2RecruitingNCT04346355
2020-03-30AmlodipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30NitrendipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30DiltiazemNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30FelodipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30CalciumNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30NifedipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30VerapamilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30NicardipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30NimodipineNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30ChlorothiazideNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30MetolazoneNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30IndapamideNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30BendroflumethiazideNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30HydrochlorothiazideNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30ChlorthalidoneNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30FosinoprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30RamiprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30PerindoprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30EnalaprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30BenazeprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30QuinaprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30CaptoprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30LisinoprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30TrandolaprilNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30OlmesartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30IrbesartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30ValsartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30LosartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30EprosartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30TelmisartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30CandesartanNovel Coronavirus Infectious Disease (COVID-19)Coronavirus ACEi/ARB InvestigationPrevention4RecruitingNCT04330300
2020-03-30AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19Treatment2RecruitingNCT04329832
2020-03-30HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19Treatment2RecruitingNCT04329832
2020-03-30BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)BCG Vaccination to Protect Healthcare Workers Against COVID-19Prevention3RecruitingNCT04327206
2020-03-30TocilizumabNovel Coronavirus Infectious Disease (COVID-19)CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)Treatment2Active Not RecruitingNCT04331808
2020-03-30HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of CareTreatment4Enrolling by InvitationNCT04334967
2020-03-29HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)Prevention2 / 3RecruitingNCT04318444
2020-03-29FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19TreatmentNot AvailableEnrolling by InvitationNCT04376814
2020-03-29LopinavirNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19TreatmentNot AvailableEnrolling by InvitationNCT04376814
2020-03-29RitonavirNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19TreatmentNot AvailableEnrolling by InvitationNCT04376814
2020-03-29HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19TreatmentNot AvailableEnrolling by InvitationNCT04376814
2020-03-29HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine for COVID-19Treatment3RecruitingNCT04342221
2020-03-28AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)Treatment3RecruitingNCT04321278
2020-03-28HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)Treatment3RecruitingNCT04321278
2020-03-28SarilumabNovel Coronavirus Infectious Disease (COVID-19)Sarilumab COVID-19Treatment3RecruitingNCT04327388
2020-03-28AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Effectiveness of Hydroxychloroquine in Covid-19 PatientsTreatment3Not Yet RecruitingNCT04328272
2020-03-28HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Effectiveness of Hydroxychloroquine in Covid-19 PatientsTreatment3Not Yet RecruitingNCT04328272
2020-03-27NaproxenNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 InfectionTreatment3Not Yet RecruitingNCT04325633
2020-03-27SarilumabNovel Coronavirus Infectious Disease (COVID-19)Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARITreatment2 / 3RecruitingNCT04324073
2020-03-27LosartanNovel Coronavirus Infectious Disease (COVID-19)Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 InfectionPrevention4RecruitingNCT04340557
2020-03-26HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized PatientsTreatment3RecruitingNCT04345692
2020-03-26AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial FloraTreatment2RecruitingNCT04366089
2020-03-26HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial FloraTreatment2RecruitingNCT04366089
2020-03-26RemdesivirNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2Treatment2 / 3Not Yet RecruitingNCT04321616
2020-03-26HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2Treatment2 / 3Not Yet RecruitingNCT04321616
2020-03-25FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19Treatment3Active Not RecruitingNCT04336904
2020-03-25BCG vaccineNovel Coronavirus Infectious Disease (COVID-19)Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG VaccinePrevention3RecruitingNCT04328441
2020-03-25LosartanNovel Coronavirus Infectious Disease (COVID-19)Study of Open Label Losartan in COVID-19Treatment1RecruitingNCT04335123
2020-03-25HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Norwegian Coronavirus Disease 2019 StudyTreatment4RecruitingNCT04316377
2020-03-24SargramostimNovel Coronavirus Infectious Disease (COVID-19)Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)Treatment4RecruitingNCT04326920
2020-03-23ColchicineNovel Coronavirus Infectious Disease (COVID-19)Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)Treatment3RecruitingNCT04322682
2020-03-23Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.Treatment2WithdrawnNCT04290871
2020-03-23ChloroquineNovel Coronavirus Infectious Disease (COVID-19)Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2Treatment2RecruitingNCT04323527
2020-03-23MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory SyndromeTreatment2 / 3RecruitingNCT04323592
2020-03-22RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Trial of Treatments for COVID-19 in Hospitalized AdultsTreatment3RecruitingNCT04315948
2020-03-22Interferon beta-1aNovel Coronavirus Infectious Disease (COVID-19)Trial of Treatments for COVID-19 in Hospitalized AdultsTreatment3RecruitingNCT04315948
2020-03-22LopinavirNovel Coronavirus Infectious Disease (COVID-19)Trial of Treatments for COVID-19 in Hospitalized AdultsTreatment3RecruitingNCT04315948
2020-03-22RitonavirNovel Coronavirus Infectious Disease (COVID-19)Trial of Treatments for COVID-19 in Hospitalized AdultsTreatment3RecruitingNCT04315948
2020-03-22HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Trial of Treatments for COVID-19 in Hospitalized AdultsTreatment3RecruitingNCT04315948
2020-03-21HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine in COVID-19 PatientsTreatment2RecruitingNCT04394442
2020-03-21Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19Treatment2RecruitingNCT04306393
2020-03-21Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19Treatment2RecruitingNCT04305457
2020-03-20ColchicineNovel Coronavirus Infectious Disease (COVID-19)The Effects of Standard Protocol With or Without Colchicine in Covid-19 InfectionTreatment2RecruitingNCT04360980
2020-03-20HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 PandemiaNot AvailableRecruitingNCT04326725
2020-03-19TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)Treatment2RecruitingNCT04317092
2020-03-19HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Randomized Evaluation of COVID-19 TherapyTreatment2 / 3RecruitingNCT04381936
2020-03-19TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Randomized Evaluation of COVID-19 TherapyTreatment2 / 3RecruitingNCT04381936
2020-03-19LopinavirNovel Coronavirus Infectious Disease (COVID-19)Randomized Evaluation of COVID-19 TherapyTreatment2 / 3RecruitingNCT04381936
2020-03-19RitonavirNovel Coronavirus Infectious Disease (COVID-19)Randomized Evaluation of COVID-19 TherapyTreatment2 / 3RecruitingNCT04381936
2020-03-19AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Randomized Evaluation of COVID-19 TherapyTreatment2 / 3RecruitingNCT04381936
2020-03-19TocilizumabCOVID-19 PneumoniaTocilizumab in COVID-19 Pneumonia (TOCIVID-19)Treatment2RecruitingNCT04317092
2020-03-18SarilumabNovel Coronavirus Infectious Disease (COVID-19)Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19Treatment2 / 3RecruitingNCT04315298
2020-03-18DanoprevirNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionTreatment4RecruitingNCT04345276
2020-03-18RitonavirNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionTreatment4RecruitingNCT04345276
2020-03-18HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialTreatment2RecruitingNCT04330690
2020-03-18LopinavirNovel Coronavirus Infectious Disease (COVID-19)Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialTreatment2RecruitingNCT04330690
2020-03-18RitonavirNovel Coronavirus Infectious Disease (COVID-19)Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialTreatment2RecruitingNCT04330690
2020-03-18RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialTreatment2RecruitingNCT04330690
2020-03-17BevacizumabNovel Coronavirus Infectious Disease (COVID-19)Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCTTreatmentNot AvailableRecruitingNCT04305106
2020-03-17HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2Treatment3RecruitingNCT04308668
2020-03-17BevacizumabCOVID-19 PneumoniaBevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCTTreatmentNot AvailableRecruitingNCT04305106
2020-03-16LopinavirNovel Coronavirus Infectious Disease (COVID-19)Baricitinib Therapy in COVID-19Treatment2 / 3CompletedNCT04358614
2020-03-16RitonavirNovel Coronavirus Infectious Disease (COVID-19)Baricitinib Therapy in COVID-19Treatment2 / 3CompletedNCT04358614
2020-03-16BaricitinibNovel Coronavirus Infectious Disease (COVID-19)Baricitinib Therapy in COVID-19Treatment2 / 3CompletedNCT04358614
2020-03-16mRNA-1273Novel Coronavirus Infectious Disease (COVID-19)Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)Prevention1RecruitingNCT04283461
2020-03-16Ad5-nCoVNovel Coronavirus Infectious Disease (COVID-19)Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy AdultsPrevention1Active Not RecruitingNCT04313127
2020-03-16Interferon beta-1aNovel Coronavirus Infectious Disease (COVID-19)Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) InfectionTreatment2RecruitingNCT04385095
2020-03-15AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19TreatmentNot AvailableRecruitingNCT04399746
2020-03-15CholecalciferolNovel Coronavirus Infectious Disease (COVID-19)Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19TreatmentNot AvailableRecruitingNCT04399746
2020-03-15IvermectinNovel Coronavirus Infectious Disease (COVID-19)Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19TreatmentNot AvailableRecruitingNCT04399746
2020-03-15RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care TreatmentTreatment3RecruitingNCT04292730
2020-03-15HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Antimalarial and Covid 19 in Rheumatoid ArthritisNot AvailableCompletedNCT04389320
2020-03-14LopinavirNovel Coronavirus Infectious Disease (COVID-19)Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)TreatmentNot AvailableNot Yet RecruitingNCT04295551
2020-03-14RitonavirNovel Coronavirus Infectious Disease (COVID-19)Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)TreatmentNot AvailableNot Yet RecruitingNCT04295551
2020-03-12MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Early Short Course Corticosteroids in COVID-19Not AvailableCompletedNCT04374071
2020-03-12TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab for SARS-CoV2 Severe PneumonitisTreatment2Active Not RecruitingNCT04315480
2020-03-11HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2TerminatedNCT04307693
2020-03-11LopinavirNovel Coronavirus Infectious Disease (COVID-19)Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2TerminatedNCT04307693
2020-03-11RitonavirNovel Coronavirus Infectious Disease (COVID-19)Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2TerminatedNCT04307693
2020-03-09Enfortumab vedotinNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Treatment2Active Not RecruitingNCT04225117
2020-03-08FavipiravirNovel Coronavirus Infectious Disease (COVID-19)Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019TreatmentNot AvailableRecruitingNCT04310228
2020-03-08TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019TreatmentNot AvailableRecruitingNCT04310228
2020-03-06DAS-181Novel Coronavirus Infectious Disease (COVID-19)DAS181 for Severe COVID-19: Compassionate UseTreatmentNot AvailableCompletedNCT04324489
2020-03-06RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)Treatment3RecruitingNCT04292899
2020-03-05TetrandrineNovel Coronavirus Infectious Disease (COVID-19)Tetrandrine Tablets Used in the Treatment of COVID-19Treatment4Enrolling by InvitationNCT04308317
2020-03-05Albumin humanNovel Coronavirus Infectious Disease (COVID-19)Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)Treatment2RecruitingNCT04288102
2020-03-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or DeathTreatment0Not Yet RecruitingNCT04323631
2020-03-01HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Bacteriotherapy in the Treatment of COVID-19Not AvailableActive Not RecruitingNCT04368351
2020-03-01AzithromycinNovel Coronavirus Infectious Disease (COVID-19)Bacteriotherapy in the Treatment of COVID-19Not AvailableActive Not RecruitingNCT04368351
2020-03-01Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 InfectionTreatment2WithdrawnNCT04290858
2020-03-01OseltamivirNovel Coronavirus Infectious Disease (COVID-19)Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019Treatment0Active Not RecruitingNCT04371601
2020-03-01OseltamivirCOVID-19 PneumoniaSafety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019Treatment0Active Not RecruitingNCT04371601
2020-02-27GilteritinibNovel Coronavirus Infectious Disease (COVID-19)A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT04240002
2020-02-27CytarabineNovel Coronavirus Infectious Disease (COVID-19)A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT04240002
2020-02-27FilgrastimNovel Coronavirus Infectious Disease (COVID-19)A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT04240002
2020-02-27FludarabineNovel Coronavirus Infectious Disease (COVID-19)A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT04240002
2020-02-23LopinavirNovel Coronavirus Infectious Disease (COVID-19)The Clinical Study of Carrimycin on Treatment Patients With COVID-19Treatment4Not Yet RecruitingNCT04286503
2020-02-23ChloroquineNovel Coronavirus Infectious Disease (COVID-19)The Clinical Study of Carrimycin on Treatment Patients With COVID-19Treatment4Not Yet RecruitingNCT04286503
2020-02-23RitonavirNovel Coronavirus Infectious Disease (COVID-19)The Clinical Study of Carrimycin on Treatment Patients With COVID-19Treatment4Not Yet RecruitingNCT04286503
2020-02-23UmifenovirNovel Coronavirus Infectious Disease (COVID-19)The Clinical Study of Carrimycin on Treatment Patients With COVID-19Treatment4Not Yet RecruitingNCT04286503
2020-02-22FingolimodNovel Coronavirus Infectious Disease (COVID-19)Fingolimod in COVID-19Treatment2RecruitingNCT04280588
2020-02-21RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Adaptive COVID-19 Treatment Trial (ACTT)Treatment3RecruitingNCT04280705
2020-02-20ThalidomideNovel Coronavirus Infectious Disease (COVID-19)The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) PneumoniaTreatment2Not Yet RecruitingNCT04273529
2020-02-20TocilizumabNovel Coronavirus Infectious Disease (COVID-19)Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19Not AvailableRecruitingNCT04306705
2020-02-18ThalidomideNovel Coronavirus Infectious Disease (COVID-19)The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19Treatment2Not Yet RecruitingNCT04273581
2020-02-17RitonavirNovel Coronavirus Infectious Disease (COVID-19)Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus InfectionTreatment4CompletedNCT04291729
2020-02-17RitonavirCOVID-19 PneumoniaEvaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus InfectionTreatment4CompletedNCT04291729
2020-02-16BromhexineNovel Coronavirus Infectious Disease (COVID-19)Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04273763
2020-02-15AcetylcysteinePulmonary Fibrosis Due to 2019-nCoVTreatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng HuayuTreatment2RecruitingNCT04279197
2020-02-15AcetylcysteineNovel Coronavirus Infectious Disease (COVID-19)Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng HuayuTreatment2RecruitingNCT04279197
2020-02-15BevacizumabNovel Coronavirus Infectious Disease (COVID-19)Bevacizumab in Severe or Critical Patients With COVID-19 PneumoniaTreatment2 / 3RecruitingNCT04275414
2020-02-14MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Corticosteroids in COVID-19TreatmentNot AvailableCompletedNCT04273321
2020-02-14Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected PneumoniaTreatment2RecruitingNCT04264533
2020-02-14WaterNovel Coronavirus Infectious Disease (COVID-19)Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected PneumoniaTreatment2RecruitingNCT04264533
2020-02-13Magnesium hydroxideNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male ParticipantsTreatment1Active Not RecruitingNCT04269356
2020-02-12RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Mild/Moderate 2019-nCoV Remdesivir RCTTreatment3RecruitingNCT04252664
2020-02-10EmicizumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsTreatment3Active Not RecruitingNCT04158648
2020-02-10RibavirinNovel Coronavirus Infectious Disease (COVID-19)Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentTreatment2RecruitingNCT04276688
2020-02-10Interferon beta-1bNovel Coronavirus Infectious Disease (COVID-19)Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentTreatment2RecruitingNCT04276688
2020-02-10LopinavirNovel Coronavirus Infectious Disease (COVID-19)Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentTreatment2RecruitingNCT04276688
2020-02-10RitonavirNovel Coronavirus Infectious Disease (COVID-19)Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentTreatment2RecruitingNCT04276688
2020-02-10Acetylsalicylic acidNovel Coronavirus Infectious Disease (COVID-19)Protective Effect of Aspirin on COVID-19 PatientsTreatment2 / 3Enrolling by InvitationNCT04365309
2020-02-10Human immunoglobulin GNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected PneumoniaTreatment2 / 3Not Yet RecruitingNCT04261426
2020-02-09SildenafilNovel Coronavirus Infectious Disease (COVID-19)A Pilot Study of Sildenafil in COVID-19Treatment3RecruitingNCT04304313
2020-02-07LopinavirNovel Coronavirus Infectious Disease (COVID-19)Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus InfectionTreatmentNot AvailableNot Yet RecruitingNCT04261907
2020-02-07RitonavirNovel Coronavirus Infectious Disease (COVID-19)Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus InfectionTreatmentNot AvailableNot Yet RecruitingNCT04261907
2020-02-07TMC-310911Novel Coronavirus Infectious Disease (COVID-19)Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus InfectionTreatmentNot AvailableNot Yet RecruitingNCT04261907
2020-02-07UmifenovirNovel Coronavirus Infectious Disease (COVID-19)Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel CoronavirusTreatment4Not Yet RecruitingNCT04260594
2020-02-06HydroxychloroquineNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )Treatment3CompletedNCT04261517
2020-02-06RemdesivirNovel Coronavirus Infectious Disease (COVID-19)Severe 2019-nCoV Remdesivir RCTTreatment3RecruitingNCT04257656
2020-02-01Angiotensin IINovel Coronavirus Infectious Disease (COVID-19)Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19TreatmentNot AvailableWithdrawnNCT04287686
2020-02-01MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)The Efficacy of Different Hormone Doses in 2019-nCoV Severe PneumoniaTreatment4RecruitingNCT04263402
2020-02-01RitonavirNovel Coronavirus Infectious Disease (COVID-19)A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV PneumoniaTreatment3RecruitingNCT04261270
2020-02-01OseltamivirNovel Coronavirus Infectious Disease (COVID-19)A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV PneumoniaTreatment3RecruitingNCT04261270
2020-02-01OseltamivirNovel Coronavirus Infectious Disease (COVID-19)A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV PneumoniaTreatment4RecruitingNCT04255017
2020-02-01LopinavirNovel Coronavirus Infectious Disease (COVID-19)A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV PneumoniaTreatment4RecruitingNCT04255017
2020-02-01RitonavirNovel Coronavirus Infectious Disease (COVID-19)A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV PneumoniaTreatment4RecruitingNCT04255017
2020-02-01RitonavirCOVID-19 PneumoniaA Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV PneumoniaTreatment3RecruitingNCT04261270
2020-02-01OseltamivirCOVID-19 PneumoniaA Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV PneumoniaTreatment3RecruitingNCT04261270
2020-01-30DarunavirNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoVTreatment3RecruitingNCT04252274
2020-01-30CobicistatNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoVTreatment3RecruitingNCT04252274
2020-01-27EnzalutamideNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerTreatment1Active Not RecruitingNCT04094519
2020-01-27RosuvastatinNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerTreatment1Active Not RecruitingNCT04094519
2020-01-27DigoxinNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerTreatment1Active Not RecruitingNCT04094519
2020-01-26MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory FailureTreatment2 / 3RecruitingNCT04244591
2020-01-25UmifenovirNovel Coronavirus Infectious Disease (COVID-19)A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)Treatment4Not Yet RecruitingNCT04246242
2020-01-22RitonavirNovel Coronavirus Infectious Disease (COVID-19)Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 InfectionTreatmentNot AvailableRecruitingNCT04251871
2020-01-22LopinavirNovel Coronavirus Infectious Disease (COVID-19)Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 InfectionTreatmentNot AvailableRecruitingNCT04251871
2019-12-03AdalimumabNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTreatment3Active Not RecruitingNCT04115748
2019-12-03FilgotinibNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTreatment3Active Not RecruitingNCT04115748
2019-12-02MethylprednisoloneNovel Coronavirus Infectious Disease (COVID-19)Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With PneumoniaTreatment2RecruitingNCT03852537
2019-11-18PentoxifyllineNovel Coronavirus Infectious Disease (COVID-19)Pentoxifylline in Diabetic Kidney DiseaseTreatment4Active Not RecruitingNCT03625648
2019-11-14FamotidineNovel Coronavirus Infectious Disease (COVID-19)A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy ParticipantsTreatment1Active Not RecruitingNCT04175925
2019-10-21Apadamtase alfaNovel Coronavirus Infectious Disease (COVID-19)A Study of SHP655 (rADAMTS13) in Sickle Cell DiseaseTreatment1 / 2Active Not RecruitingNCT03997760
2019-09-18GuanfacineNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged Release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attentiondeficit/Hyperactivity Disorder (ADHD)Treatment4Active Not RecruitingNCT04085172
2019-09-18AtomoxetineNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged Release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attentiondeficit/Hyperactivity Disorder (ADHD)Treatment4Active Not RecruitingNCT04085172
2019-09-13FremanezumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive DisorderPrevention4Active Not RecruitingNCT04041284
2019-09-11SertralineNovel Coronavirus Infectious Disease (COVID-19)Predicting SSRI Efficacy in Veterans With PTSDScreening4Active Not RecruitingNCT04183205
2019-08-30LanadelumabNovel Coronavirus Infectious Disease (COVID-19)A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of AgePrevention3Active Not RecruitingNCT04070326
2019-08-22IsavuconazoniumNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric ParticipantsTreatment2Active Not RecruitingNCT03816176
2019-08-06DeutetrabenazineNovel Coronavirus Infectious Disease (COVID-19)A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and AdolescentsTreatment3Active Not RecruitingNCT03813238
2019-07-29LenalidomideNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)Treatment1Active Not RecruitingNCT03984097
2019-07-29DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)Treatment1Active Not RecruitingNCT03984097
2019-07-29BortezomibNovel Coronavirus Infectious Disease (COVID-19)A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)Treatment1Active Not RecruitingNCT03984097
2019-07-10FezolinetantNovel Coronavirus Infectious Disease (COVID-19)A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through MenopauseTreatment3Active Not RecruitingNCT04003155
2019-07-10FezolinetantNovel Coronavirus Infectious Disease (COVID-19)A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through MenopauseTreatment3Active Not RecruitingNCT04003389
2019-07-10FezolinetantNovel Coronavirus Infectious Disease (COVID-19)A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2Treatment3Active Not RecruitingNCT04003142
2019-07-10PevonedistatNovel Coronavirus Infectious Disease (COVID-19)A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic ImpairmentOther1Active Not RecruitingNCT03814005
2019-07-10AzacitidineNovel Coronavirus Infectious Disease (COVID-19)A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic ImpairmentOther1Active Not RecruitingNCT03814005
2019-07-02RelatlimabNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 TreatmentTreatment1Active Not RecruitingNCT03978611
2019-07-02IpilimumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 TreatmentTreatment1Active Not RecruitingNCT03978611
2019-06-19AtezolizumabNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT03730012
2019-06-19GilteritinibNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)Treatment1 / 2Active Not RecruitingNCT03730012
2019-05-31FremanezumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With FibromyalgiaTreatment2Active Not RecruitingNCT03965091
2019-05-23DAS-181Novel Coronavirus Infectious Disease (COVID-19)Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyTreatment3RecruitingNCT03808922
2019-03-13Anti-inhibitor coagulant complexNovel Coronavirus Infectious Disease (COVID-19)FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)Treatment3Active Not RecruitingNCT02764489
2019-02-21MetforminNovel Coronavirus Infectious Disease (COVID-19)Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesTreatment4RecruitingNCT02915198
2019-01-24IxazomibNovel Coronavirus Infectious Disease (COVID-19)A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)Treatment3Active Not RecruitingNCT03748953
2019-01-24Streptococcus pneumoniae type 33f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 17f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 10a capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 15b capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 11a capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 22f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 2 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 8 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 9n capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 12f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 20 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 5 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 18c capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Corynebacterium diphtheriaeNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 1 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 6b capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 9v capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 4 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 7f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 3 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 19a capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 23f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 19f capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 14 capsular polysaccharide antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24Streptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigenNovel Coronavirus Infectious Disease (COVID-19)A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccinePrevention1 / 2Active Not RecruitingNCT03803202
2019-01-24IxazomibNovel Coronavirus Infectious Disease (COVID-19)Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)Treatment3Active Not RecruitingNCT04371770
2019-01-14PembrolizumabNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP1951 in Subjects With Advanced Solid TumorsTreatment1Active Not RecruitingNCT03799003
2018-12-20RelamorelinNovel Coronavirus Infectious Disease (COVID-19)Diabetic Gastroparesis Study 05Treatment3Active Not RecruitingNCT03786380
2018-12-07Coagulation Factor IX (Recombinant)Novel Coronavirus Infectious Disease (COVID-19)RIXUBIS PMS India (RIXUBIS PMS)Prevention4Active Not RecruitingNCT03565237
2018-11-08Ascorbic acidNovel Coronavirus Infectious Disease (COVID-19)Lessening Organ Dysfunction With VITamin CTreatment3RecruitingNCT03680274
2018-09-24Human immunoglobulin GNovel Coronavirus Infectious Disease (COVID-19)Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)Not AvailableActive Not RecruitingNCT03716700
2018-08-28Isopropyl alcoholNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065Treatment3RecruitingNCT03398135
2018-08-28RisankizumabNovel Coronavirus Infectious Disease (COVID-19)A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065Treatment3RecruitingNCT03398135
2018-07-13Mycophenolate mofetilNovel Coronavirus Infectious Disease (COVID-19)A Staged Study of the Safety and Effectiveness of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Dry Age-related Macular DegenerationTreatment1 / 2Active Not RecruitingNCT03178149
2018-07-13TacrolimusNovel Coronavirus Infectious Disease (COVID-19)A Staged Study of the Safety and Effectiveness of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Dry Age-related Macular DegenerationTreatment1 / 2Active Not RecruitingNCT03178149
2018-06-25OntamalimabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)Treatment3Active Not RecruitingNCT03559517
2018-06-11OntamalimabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)Treatment3Active Not RecruitingNCT03566823
2018-04-26PomalidomideNovel Coronavirus Infectious Disease (COVID-19)A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)Treatment1 / 2Active Not RecruitingNCT03439280
2018-04-26DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)Treatment1 / 2Active Not RecruitingNCT03439280
2018-04-03ChlorhexidineNovel Coronavirus Infectious Disease (COVID-19)STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)Treatment2RecruitingNCT03489629
2018-04-03TrimethoprimNovel Coronavirus Infectious Disease (COVID-19)STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)Treatment2RecruitingNCT03489629
2018-04-03SulfamethoxazoleNovel Coronavirus Infectious Disease (COVID-19)STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)Treatment2RecruitingNCT03489629
2018-04-03MupirocinNovel Coronavirus Infectious Disease (COVID-19)STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)Treatment2RecruitingNCT03489629
2018-04-03MinocyclineNovel Coronavirus Infectious Disease (COVID-19)STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)Treatment2RecruitingNCT03489629
2018-03-05Beroctocog alfaNovel Coronavirus Infectious Disease (COVID-19)Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A ParticipantsPrevention1 / 2Active Not RecruitingNCT03370172
2018-03-05Onasemnogene abeparvovecNovel Coronavirus Infectious Disease (COVID-19)Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A ParticipantsPrevention1 / 2Active Not RecruitingNCT03370172
2018-02-16RelamorelinNovel Coronavirus Infectious Disease (COVID-19)Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02Treatment3Active Not RecruitingNCT03426345
2018-02-15Parathyroid hormoneNovel Coronavirus Infectious Disease (COVID-19)Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Symptoms Improvement and Metabolic Control Among Adults With HypoparathyroidismTreatment4Active Not RecruitingNCT03324880
2018-02-09OntamalimabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTreatment3Active Not RecruitingNCT03259334
2018-02-01RelamorelinNovel Coronavirus Infectious Disease (COVID-19)A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04Treatment3Active Not RecruitingNCT03383146
2018-01-24CorticotropinNovel Coronavirus Infectious Disease (COVID-19)Acthar Gel in Participants With Pulmonary SarcoidosisTreatment4Active Not RecruitingNCT03320070
2017-12-19SargramostimNovel Coronavirus Infectious Disease (COVID-19)Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial DiseaseTreatment2SuspendedNCT03304821
2017-12-18Vonicog AlfaNovel Coronavirus Infectious Disease (COVID-19)BAX 111 rVWF in PediatricsTreatment3Active Not RecruitingNCT02932618
2017-12-18Von Willebrand Factor HumanNovel Coronavirus Infectious Disease (COVID-19)BAX 111 rVWF in PediatricsTreatment3Active Not RecruitingNCT02932618
2017-12-18Antihemophilic factor, human recombinantNovel Coronavirus Infectious Disease (COVID-19)BAX 111 rVWF in PediatricsTreatment3Active Not RecruitingNCT02932618
2017-12-05OntamalimabNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTreatment3Active Not RecruitingNCT03259308
2017-11-28AzacitidineNovel Coronavirus Infectious Disease (COVID-19)Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)Treatment3Active Not RecruitingNCT03268954
2017-11-28PevonedistatNovel Coronavirus Infectious Disease (COVID-19)Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)Treatment3Active Not RecruitingNCT03268954
2017-10-24NitrogenNovel Coronavirus Infectious Disease (COVID-19)Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) InfectionsTreatment2Active Not RecruitingNCT03331445
2017-10-24Nitric OxideNovel Coronavirus Infectious Disease (COVID-19)Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) InfectionsTreatment2Active Not RecruitingNCT03331445
2017-10-16CisplatinNovel Coronavirus Infectious Disease (COVID-19)Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal CarcinomaTreatment2RecruitingNCT03323463
2017-10-16CarboplatinNovel Coronavirus Infectious Disease (COVID-19)Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal CarcinomaTreatment2RecruitingNCT03323463
2017-10-04DexamethasoneNovel Coronavirus Infectious Disease (COVID-19)A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)Treatment1 / 2Active Not RecruitingNCT03215030
2017-09-29RelamorelinNovel Coronavirus Infectious Disease (COVID-19)A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01Treatment3Active Not RecruitingNCT03285308
2017-09-21ZonisamideNovel Coronavirus Infectious Disease (COVID-19)Interdisciplinary Study of A Novel Anticonvulsant in AlcoholismTreatment3Active Not RecruitingNCT02901041
2017-07-26PrednisoneNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTreatment2Active Not RecruitingNCT03207815
2017-07-26FilgotinibNovel Coronavirus Infectious Disease (COVID-19)Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTreatment2Active Not RecruitingNCT03207815
2017-05-22Mycophenolate mofetilNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22BleselumabNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22MethylprednisoneNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22BasiliximabNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22TacrolimusNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22PrednisoneNovel Coronavirus Infectious Disease (COVID-19)Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsTreatment2Active Not RecruitingNCT02921789
2017-05-22CorticotropinNovel Coronavirus Infectious Disease (COVID-19)Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple SclerosisTreatment4SuspendedNCT03126760
2017-05-22CorticotropinNovel Coronavirus Infectious Disease (COVID-19)Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple SclerosisTreatment4SuspendedNCT03126760
2016-11-28RelatlimabNovel Coronavirus Infectious Disease (COVID-19)Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsTreatment1Active Not RecruitingNCT02966548
2016-11-28NivolumabNovel Coronavirus Infectious Disease (COVID-19)Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsTreatment1Active Not RecruitingNCT02966548
2016-04-29Human immunoglobulin GNovel Coronavirus Infectious Disease (COVID-19)Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPTreatment3Active Not RecruitingNCT02549170
2016-04-29Vorhyaluronidase alfaNovel Coronavirus Infectious Disease (COVID-19)Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPTreatment3Active Not RecruitingNCT02549170
2015-12-21FidaxomicinNovel Coronavirus Infectious Disease (COVID-19)Optimal Treatment for Recurrent Clostridium DifficileTreatment4Active Not RecruitingNCT02667418
2015-12-21VancomycinNovel Coronavirus Infectious Disease (COVID-19)Optimal Treatment for Recurrent Clostridium DifficileTreatment4Active Not RecruitingNCT02667418
2015-11-12Antihemophilic Factor (Recombinant), PEGylatedNovel Coronavirus Infectious Disease (COVID-19)Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years of Age With Severe Hemophilia ATreatment3Active Not RecruitingNCT02615691
2015-02-26GilteritinibNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.Treatment1 / 2Active Not RecruitingNCT02310321
2015-02-26IdarubicinNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.Treatment1 / 2Active Not RecruitingNCT02310321
2015-02-26CytarabineNovel Coronavirus Infectious Disease (COVID-19)A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.Treatment1 / 2Active Not RecruitingNCT02310321
2014-01-16AtazanavirNovel Coronavirus Infectious Disease (COVID-19)Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric ParticipantsTreatment2 / 3Active Not RecruitingNCT02016924
2014-01-16DarunavirNovel Coronavirus Infectious Disease (COVID-19)Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric ParticipantsTreatment2 / 3Active Not RecruitingNCT02016924
2014-01-16CobicistatNovel Coronavirus Infectious Disease (COVID-19)Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric ParticipantsTreatment2 / 3Active Not RecruitingNCT02016924
2011-06-29Antihemophilic factor, human recombinantNovel Coronavirus Infectious Disease (COVID-19)ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)Not AvailableActive Not RecruitingNCT02078427
Not AvailableEculizumabNovel Coronavirus Infectious Disease (COVID-19)SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19Not AvailableAvailableNCT04355494
Not AvailableNitric OxideNovel Coronavirus Infectious Disease (COVID-19)Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19Not AvailableAvailableNCT04358588
Not AvailableRuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionNot AvailableAvailableNCT04355793
Not AvailableRuxolitinibNovel Coronavirus Infectious Disease (COVID-19)Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 IllnessNot AvailableAvailableNCT04337359
Not AvailableRemdesivirNovel Coronavirus Infectious Disease (COVID-19)Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)Not AvailableAvailableNCT04323761
Not AvailableEculizumabNovel Coronavirus Infectious Disease (COVID-19)Eculizumab (Soliris) in Covid-19 Infected PatientsNot AvailableAvailableNCT04288713
Not AvailableRemestemcel-LNovel Coronavirus Infectious Disease (COVID-19)Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 InfectionNot AvailableNo Longer AvailableNCT04366830
Not AvailableTrastuzumabNovel Coronavirus Infectious Disease (COVID-19)An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicNot AvailableAvailableNCT04395508
Not AvailablePertuzumabNovel Coronavirus Infectious Disease (COVID-19)An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicNot AvailableAvailableNCT04395508
Not AvailableRemdesivirNovel Coronavirus Infectious Disease (COVID-19)Expanded Access Remdesivir (RDV; GS-5734™)Not AvailableAvailableNCT04302766
Clinical Trial Summary by Drug
DrugCount
Hydroxychloroquine161
Azithromycin63
Ritonavir39
Tocilizumab35
Lopinavir34
Chloroquine24
Favipiravir14
Ivermectin14
Ruxolitinib14
Methylprednisolone13
Heparin13
Remdesivir12
Baricitinib12
Nitric Oxide12
Colchicine11
Sarilumab10
Nitazoxanide10
Dexamethasone10
Anakinra9
Enoxaparin9
Losartan9
Angiotensin II8
Ascorbic acid8
Oseltamivir7
Sodium chloride6
Human immunoglobulin G6
BCG vaccine6
Telmisartan6
Acetylsalicylic acid5
Clazakizumab5
Budesonide5
Povidone-iodine5
Camostat5
Ontamalimab4
Relamorelin4
Bevacizumab4
Nivolumab4
Interferon beta-1a4
Umifenovir4
Prednisone4
Isotretinoin4
Imatinib4
DAS-1814
Tranexamic acid4
Fezolinetant3
Gilteritinib3
Tacrolimus3
Interferon beta-1b3
Eculizumab3
Canakinumab3
Dornase alfa3
Sirolimus3
Rivaroxaban3
Acetylcysteine3
Ribavirin3
Ad5-nCoV3
Calcium3
Captopril3
Bromhexine3
Famotidine3
Peginterferon lambda-1a3
Valsartan3
Candesartan3
Levamisole3
Mavrilimumab3
Ciclesonide3
Doxycycline3
Niclosamide3
Deferoxamine3
Hydrocortisone3
Ixazomib3
Antihemophilic factor, human recombinant2
Corticotropin2
Mycophenolate mofetil2
Relatlimab2
Azacitidine2
Pevonedistat2
Fremanezumab2
Filgotinib2
Cobicistat2
Darunavir2
Thalidomide2
Cytarabine2
Sargramostim2
Ramipril2
Clopidogrel2
Defibrotide2
Chlorhexidine2
Simvastatin2
Formoterol2
Leronlimab2
Cholecalciferol2
Enalapril2
Sulfamethoxazole2
Trimethoprim2
Siltuximab2
Dexmedetomidine2
Sevoflurane2
Lenalidomide2
Verapamil2
Calcifediol2
Clavulanic acid2
Amoxicillin2
Remestemcel-L2
Selinexor2
Esomeprazole2
Diltiazem2
Ibuprofen2
Zinc sulfate2
Fondaparinux2
Chlorpromazine2
Ozone2
Lanadelumab2
Methylene blue2
Ravulizumab2
Acalabrutinib2
Tinzaparin2
Alteplase2
Olmesartan2
Irbesartan2
Eprosartan2
Atorvastatin2
Dapagliflozin2
Inosine pranobex2
Pembrolizumab2
Protoporphyrin2
Tofacitinib2
Aviptadil2
Linagliptin2
Nitrogen2
Pertuzumab1
Trastuzumab1
Atazanavir1
Idarubicin1
Antihemophilic Factor (Recombinant), PEGylated1
Vancomycin1
Fidaxomicin1
Vorhyaluronidase alfa1
Corticotropin1
Basiliximab1
Methylprednisone1
Bleselumab1
Zonisamide1
Carboplatin1
Cisplatin1
Von Willebrand Factor Human1
Vonicog Alfa1
Parathyroid hormone1
Onasemnogene abeparvovec1
Beroctocog alfa1
Minocycline1
Mupirocin1
Pomalidomide1
Risankizumab1
Isopropyl alcohol1
Coagulation Factor IX (Recombinant)1
Streptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigen1
Streptococcus pneumoniae type 14 capsular polysaccharide antigen1
Streptococcus pneumoniae type 19f capsular polysaccharide antigen1
Streptococcus pneumoniae type 23f capsular polysaccharide antigen1
Streptococcus pneumoniae type 19a capsular polysaccharide antigen1
Streptococcus pneumoniae type 3 capsular polysaccharide antigen1
Streptococcus pneumoniae type 7f capsular polysaccharide antigen1
Streptococcus pneumoniae type 4 capsular polysaccharide antigen1
Streptococcus pneumoniae type 9v capsular polysaccharide antigen1
Streptococcus pneumoniae type 6b capsular polysaccharide antigen1
Streptococcus pneumoniae type 1 capsular polysaccharide antigen1
Corynebacterium diphtheriae1
Streptococcus pneumoniae type 18c capsular polysaccharide antigen1
Streptococcus pneumoniae type 5 capsular polysaccharide antigen1
Streptococcus pneumoniae type 20 capsular polysaccharide antigen1
Streptococcus pneumoniae type 12f capsular polysaccharide antigen1
Streptococcus pneumoniae type 9n capsular polysaccharide antigen1
Streptococcus pneumoniae type 8 capsular polysaccharide antigen1
Streptococcus pneumoniae type 2 capsular polysaccharide antigen1
Streptococcus pneumoniae type 22f capsular polysaccharide antigen1
Streptococcus pneumoniae type 11a capsular polysaccharide antigen1
Streptococcus pneumoniae type 15b capsular polysaccharide antigen1
Streptococcus pneumoniae type 10a capsular polysaccharide antigen1
Streptococcus pneumoniae type 17f capsular polysaccharide antigen1
Streptococcus pneumoniae type 33f capsular polysaccharide antigen1
Metformin1
Anti-inhibitor coagulant complex1
Atezolizumab1
Ipilimumab1
Bortezomib1
Deutetrabenazine1
Isavuconazonium1
Sertraline1
Atomoxetine1
Guanfacine1
Apadamtase alfa1
Pentoxifylline1
Adalimumab1
Digoxin1
Rosuvastatin1
Enzalutamide1
TMC-3109111
Sildenafil1
Emicizumab1
Magnesium hydroxide1
Water1
Fingolimod1
Fludarabine1
Filgrastim1
Albumin human1
Tetrandrine1
Enfortumab vedotin1
mRNA-12731
Danoprevir1
Naproxen1
Trandolapril1
Lisinopril1
Quinapril1
Benazepril1
Perindopril1
Fosinopril1
Chlorthalidone1
Hydrochlorothiazide1
Bendroflumethiazide1
Indapamide1
Metolazone1
Chlorothiazide1
Nimodipine1
Nicardipine1
Nifedipine1
Felodipine1
Nitrendipine1
Amlodipine1
Angiotensin 1-71
Salbutamol1
Memantine1
Sodium bicarbonate1
Melatonin1
Nafamostat1
Chlorine Dioxide1
Emapalumab1
Nintedanib1
Omeprazole1
Pyridostigmine1
Tirofiban1
Piclidenoson1
Mefloquine1
AT-0011
Iodine1
Povidone1
EIDD-28011
Fluvoxamine1
Clindamycin1
Primaquine1
Gimsilumab1
Icosapent1
Tradipitant1
Tenofovir disoproxil1
Emtricitabine1
Folic acid1
Propofol1
Cyclosporine1
Indomethacin1
Hydrocortisone succinate1
Lactose1
Cysteine1
Atovaquone1
Estradiol1
Pyrazinamide1
Tazobactam1
Piperacillin1
Human interferon beta1
Spironolactone1
AZD12221
Acetaminophen1
Olokizumab1
Sirukumab1
Vazegepant1
Progesterone1
Amiodarone1
Naltrexone1
Ketamine1
Regramostim1
Lenzilumab1
Melphalan1
Tridecactide1
Metenkefalin1
Almitrine1
Tamoxifen1
ABX-4641
Vidofludimus1
Zanubrutinib1
Zilucoplan1
Fluoxetine1
Methylprednisolone hemisuccinate1
Methotrexate1
Liothyronine1
Zinc1
Leflunomide1
Ibrutinib1
Clarithromycin1
Clevudine1
Etoposide1
Plitidepsin1
Mannitol1
Prazosin1
Dalteparin1
Nadroparin1
Interleukin-71
Honey1
Ambrisentan1
Poractant alfa1
Otilimab1
Sitagliptin1
Interferon alfa1
Interferon alfa-2b1
Degarelix1
Resiniferatoxin1
Ranitidine1
Alvelestat1
Tretinoin1
Artemisinin1
Artesunate1
Lucinactant1
Dipyridamole1
Ulinastatin1
Bicalutamide1
Oxytocin1
Duvelisib1
AMY-1011
Montelukast1
Ifenprodil1
Publications using DrugBank

The table below highlights current and/or recent research relating to COVID-19 that cites the use of DrugBank.

Disclaimer: These publications may be early-access, and may not have been peer reviewed.
Publication
Altınyazar V. COVİD-19 TEDAVİSİNDE ÖNERİLEN İLAÇLARIN PSİKOTROPLARLA ETKİLEŞİMLERİ. 2020
Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (COVID-19) from FDA approved drugs.
Avchaciov K, Burmistrova O, Fedichev P. AI for the repurposing of approved or investigational drugs against COVID-19. 2020 March.
Bag A, Bag A. Justicia adhatoda leaves extract is a strong remedy for COVID-19 - Case report analysis and docking based study.
Balasubramaniam M, Reis RJS. Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.
Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. 2020 March.
Cao Y, Deng Q, Dai S. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19 : An evaluation of the evidence. Travel Med Infect Dis. 2020 April.
Catapang JK, Billones JB. On the generation of novel ligands for SARS-CoV-2 protease and ACE2 receptor via constrained graph variational autoencoders. 2020.
Chakraborti S, Srinivasan N. Drug repurposing approach targeted against main protease of SARS-CoV-2 exploiting 'neighbourhood behaviour' in 3D protein structural space and 2D chemical space of small molecules.
Chakrabortya HJ. Drug Repurposing against SARS-CoV-2 RDRP - A computational quest against CoVID-19.
Chen L, Zhong and.L. Genomics functional analysis and drug screening of SARS-CoV-2. 2020.
Chen L. Genomics functional analysis and drug screening of 2019 novel coronavirus in Wuhan, China.
Chen YW, Yiu CB, Wong K. Prediction of the 2019-nCoV 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. 2019.
Chen YW, Yiu CB, Wong K. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study.
Ekins S, Mottin M, Ramos P, Sousa B, Neves B, Foil DH, Zorn KM, Braga R, Coffee M, Southan C, Puhl AC, Andrade C. Déjà vu: Stimulating Open Drug Discovery for SARS-CoV-2.
Farag AB, Wang P, Ahmed MS, Sadek HA. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning.
Galvez J, Zanni R, Galvez-Llompart M. Drugs Repurposing for Coronavirus Treatment: Computational Study Based On Molecular Topology. 2020.
Ge Y, Tian T, Huang S, Wan F, Li J. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. 2020.
Gough NR. A Combination Therapy that Eliminates COVID-19 Virus. 2020.
Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. Master Regulator Analysis of the SARS-CoV- 2/Human interactome. 2020.
Hall DC, Ji H. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 April.
Hijikata A, Shionyu-mitsuyama C, Nakae S, Shionyu M, Ota M. Knowledge-Based Structural Models of SARS-CoV-2 Proteins and Their Complex with Potential Drugs. 2020.
Horvath D, Orlov A, Osolodkin DI, Ishmukhametov AA, Marcou G. A Chemographic Audit of Anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL).
Hosseini FS, Amanlou M, Medicine E. Simeprevir, potential candidate to repurpose for coronavirus infection: Virtual screening and molecular docking study. 2020 February.
Jamal S, Singh J, Sheikh JA, Singh H, Khubaib M, Kohli S, Dobrindt U, Rahman SA, Ehtesham NZ, Hasnain SE. Molecular analyses of over hundred sixty clinical isolates of SARS-CoV-2: Insights on likely origin, evolution and spread, and possible intervention. 2020 March.
Joshi T, Mathpal S, Sharma P, Joshi T, Pundir H, Maiti P, Nand M, Chandra S. Molecular Docking Study of drug molecules from Drug Bank database against COVID-19 Mpro protein.
Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, Singh RP, Muthukumaran J, Singh AK. Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltra. 2020.
Li X, Yu J, Zhang Z, Ren J, Peluffo AE, Zhang W, Zhao Y, Yan K, Cohen D, Wang W. Network bioinformatics analysis provides insight into drug repurposing for COVID-2019. 2020 March.
Li X. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. 2020.
Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, Liu K, Zeng H, Zou Q. Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. 2020.
Liu H, Jiang T, Liu W, Zheng Z. Computational Evaluation of the COVID-19 3c-like Protease Inhibition Mechanism , and Drug Repurposing Screening.
Liu X, Wang X. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. 2020.
Mevada V, Dudhagara P, Gandhi H, Vaghamshi N. Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19.
Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. 2020 March.
Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Potentially highly potent drugs for 2019-nCoV. 2020.
Olubiyi OO, Olagunju M, Keutmann M, Strodel B. High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2. 2020 April.
Patiyal S, Kaur D, Kaur H, Sharma N, Dhall A, Raghava GPS. A web-based platform on COVID-19 to maintain Predicted Diagnostic, Drug and Vaccine candidates.
Patra A, Bhavesh NS. Virtual screening and molecular dynamics simulation suggest Valproic acid Co-A could bind to SARS-CoV2 RNA depended RNA polymerase. 2020 March.
Rao S, Lau A, So H. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization analysis. 2020.
Sandeep S. Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S) Protein-ACE2 Complex. 2020.
Senathilake KS, Samarakoon SR, Tennekoon KH. Virtual screening of inhibitors against spike glycoprotein of SARS-CoV-2: a drug repurposing approach. 2020 March.
Sharma A, Tiwari V, Sowdhamini R. Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products.
Szymkuć S, Grzybowski BA. Suggestions for second-pass anti-COVID-19 drugs based on the Artificial Intelligence measures of molecular similarity, shape and pharmacophore.
T MK, K R, James N, V S, Karuppasamy R. Discovery of Potent Covid-19 Main Protease Inhibitors Using Machine Learning Based Virtual Screening Strategy. 2020.
Talluri S. Virtual Screening Based Prediction of Potential Drugs for COVID-19. 2020.
Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) Through Computational Drug Repurposing Study.
Wei T, Wang H, Lu Y. In silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.
Xu C, Ke Z, Liu C, Wang Z, Liu D, Zhang L, Wang J, He W, Xu Z, Li Y, Yang Y, Huang Z, Lv P, Wang X, Han D, Li Y, Qiao N, Liu B. Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. 2020.
Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling , molecular docking and binding free energy calculation. 2020.
Zhang L, Zhou R. Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase. 2020 March.
Zhavoronkov A, Medicine I, Zhebrak A, Medicine I, Zagribelnyy BA, Bezrukov D. Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches. 2020.
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based Drug Repurposing for Human Coronavirus. 2020.
Zhou Y, Hou Y, Shen J, Huang Y, Martin W. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020.
References
  1. World Health Organization: Naming the coronavirus disease (COVID-19) and the virus that causes it [Link]
  2. World Health Organization: Rolling updates on Coronavirus Disease (COVID-19) [Link]
  3. World Health Organization: Q&A on coronaviruses (COVID-19) [Link]
  4. Centers on Disease Control and Prevention: Coronavirus Disease 2019 [Link]
  5. European Centre for Disease Prevention and Control: COVID-19 [Link]

Updated on June 05, 2020